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Abstract 
Introduction: The main aim was to investigate Dukes B cancer 
prognosis using array comparative genomic hybridisation (aCGH). 
The cancers were typed for microsatellite instability (MSI), APC loss 
of heterozygosity (LOH) and ploidy. A secondary aim was the 
selection, on the basis of aCGH results, of potential colorectal cancer 
genes using In Situ Hybridisation (ISH).  Sporadic adenomas were 
also investigated with aCGH to investigate the timing of 
chromosomal instability in tumourigenesis. 
Methods: Dukes B cancers collected in Oxford, Leeds and Harrow 
were examined using aCGH based on a set of 3452 BAC clones at 
~1Mb spacing. MSI was assessed using BAT26 and D5S346. 
D5S346 gave LOH at the APC gene locus. Ploidy was assessed 
using flow cytometry (FACS). From the aCGH data genes in regions 
of copy number gain were chosen for ISH analysis. 
Results: 79 Dukes B cancers (43 good outcome, 36 bad outcome on 
the basis of 5 year survival) were investigated with aCGH. The most 
commonly gained chromosomes across all cancers were 13, 20 and 
7, and the most commonly lost were 22, 18 and 14. Comparing 
survival groups; chromosome 6 was more often lost in cancers 
associated with good outcome, chromosome 16 was more often 
gained in microsatellite stable cancers associated with good 
outcome, and chromosome 22 more often gained in microsatellite 
stable cancers associated with poor outcome. Chromosome 13 
showed greater than single copy number change significantly more 
often in bad outcome cancers. Several new areas of small genomic 
gain and loss were detected. Four candidate genes were identified 
(CDX2, RHOA, FLT1 and ARHGEF1). None showed a relationship 
with outcome. Large scale chromosomal changes were found in 10 
of14 sporadic adenomas.  
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Conclusions: Array CGH did identify some difference between good 
and bad outcome Dukes B cancers. However on the basis of this 
data, the technique could not be used as a useful clinical tool to 
predict prognosis. 
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Chapter 1.  
Introduction 
 
1.1 Colorectal Cancer  
 
Colorectal cancer (CRC) accounted for 16,000 deaths in the UK in 
2003 (Steele R, 2005) and constitutes a major health problem in the 
Western world. The 5-year survival rate is approximately 45%. The 
disease has a lifetime risk in the general population of 5%. The 
incidence of the disease is equal in men and women. Rectal cancers 
account for about 30% of CRC. Within the colon 25% of cancers 
arise in the right side of the colon and 45% arise in the left. It is 
generally accepted that most colonic cancers arise from pre-existing 
adenomatous polyps (Morson et al 1966, Bussey et al 1975, Muto et 
al 1975, Granquist et al 1981, Chu et al 1986, Eide et al 1986, 
Winawer et al 1987, Vogelstein et al 1988 ), the evidence for this 
being that adenomatous tissue often accompanies cancer, sporadic 
adenomas are identical histologically to the adenomas of familial 
adenomatous polyposis, large adenomas are more likely to display 
cellular atypia than small lesions, the distribution of adenomas in the 
colon is similar to that for cancers, adenomas are found in up to a 
third of specimens resected for cancer, the incidence of CRC falls 
with screening programmes involving colonoscopy and polypectomy 
and finally that patients present with adenomas on average 5 years 
before those patients presenting with cancers.  
 
Ninety-five percent of CRC arise sporadically with approximately 5% 
related to the inherited syndromes FAP (Familial Adenomatous 
Polyposis) and HNPCC (Hereditary Non Polyposis Colorectal 
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Cancer). Other inherited conditions such as Peutz-Jeghers, Juvenile 
Polyposis, Cowden disease and mixed polyposis syndromes are also 
associated with a high risk of CRC.  
Colorectal cancers mainly exhibit one of two types of genomic 
instability, chromosomal  instability (CIN), characterised by an 
unstable chromosome number and an aneuploid/polyploid karyotype 
(Lengauer et al 1998, Fodde et al 2001) or microsatellite instability 
(MSI) due to a defective DNA mismatch repair pathway, resulting in 
sequence changes but with maintenance of a diploid karyotype 
(Modrich et al 1991, Ilyas et al 1999). A small number of cancers 
show either both or neither type of instability (Jones et al 2005). Most 
sporadic cancers and those associated with FAP are CIN+ whereas 
tumours associated with HNPCC and ~10% of sporadic CRC are 
MSI+.  
Broadly speaking colorectal cancers may be divided into three 
groups in terms of genetic factors. First, a chromosomally unstable 
microsatellite stable group showing FAP related gene mutation. 
Secondly, a microsatellite unstable chromosomally stable group of 
inherited cancers.  Thirdly, a group of sporadic, microsatellite 
unstable, chromosomally stable cancers showing CPG island 
methylation. 
 
1.2    Genetics of colorectal cancer  
1.2.1 Chromosomal Instability (CIN)  
Since this thesis is primarily involved in investigating genomic 
stability I will begin the detailed discussion of the genetics of 
colorectal cancer by considering this aspect. 
Colorectal cancers may be divided into those showing chromosomal 
instability (CIN) and those showing microsatellite instability with much 
smaller numbers showing either both types of instability or neither 
17 
 
type (Ilyas et al 1999). CIN describes cancers that show aneuploidy 
or polyploidy with large scale gains and  losses of genetic material at 
the chromosomal level.  
Debate exists as to the nature of CIN both in terms of its cause and  
its importance in tumourigenesis.  It is argued by some that CIN is 
initiated early in tumourigenesis and is essential in generating a 
mutation rate necessary for tumour development (Loeb et al 1991). 
Others argue that it is a by product of the processes essential for 
tumourigenesis and not essential per se (Tomlinson et al1999).  
Therefore a number of questions exist in relation to CIN. At what 
stage in tumorigenesis does it become evident? What causes it to 
develop? What is its importance in relation to tumorigenesis and 
once initiated how does it take place? How can it be measured? 
 
1.2.2 Timing of CIN 
By experimenting on adenomas one can attempt to discover how 
early CIN is evident.  
Sieber et al (2002) studied evidence of genomic instability in 55 small 
adenomas from 18 FAP patients with 2 APC hits. They found little 
evidence of instability using a variety of techniques including LOH 
analysis, flow cytometry (FACS) and comparative genomic 
hybridisation (CGH). CGH analysis of 3 polyps which had shown 
LOH at APC showed normal profiles indicating that LOH at APC was 
not due to physical loss of material but more likely due to somatic 
recombination.  
Shih et al (2001) assessed allelic imbalance using digital PCR in 32 
sporadic adenomas with an average size of 2mm at 1p, 5q, 8p, 15 q 
and 18q. They found allelic imbalance in respectively, 10%, 55%, 
19%, 28%, and 28% of cases. Over 90% of tumours exhibited allelic 
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imbalance at at least one site. These findings showed that allelic 
imbalance was a common event in very small adenomas and that 
these events occurred at an early stage of colorectal neoplasia.  
While these results may seem to some degree contradictory they 
both show evidence to a greater or lesser extent of a degree of early 
genomic instability without evidence necessarily of large scale 
chromosomal instability. Shih et al did not test their samples using 
FACS or CGH and therefore we cannot know this for certain, but 
allelic imbalance itself does not imply large scale chromosomal 
change as shown by the CGH experiments carried out on Sieber et 
al’s samples that had shown LOH. 
Previous experiments have looked at the timing of chromosomal 
instability as evidenced by aneuploidy using FACS (Bauer et al 1987, 
Giaretti et al 1988, Quirke et al 1986). These show that about 10% of 
low grade polyps smaller than 1cm show aneuploidy and 12-37% of 
high grade polyps greater than 1cm. Levels for frank 
adenocarcinomas are between 50% and 85%. Thus it may be seen 
that a few early adenomas demonstrate aneuploidy and that the 
percentage of lesions demonstrating aneuploidy increases with 
advancing stages of tumorigenesis.  
1.2.3 LOH in relation to CIN 
It may be seen that while aneuploidy is not widespread early in 
tumorigenesis LOH is more evident. Such LOH may be achieved in a 
number of ways: mitotic non-disjunction, loss of a segment of 
chromosome resulting from a deletion event, mitotic recombination 
between two homologous chromosomes, break-induced replication, 
recombination between two non-homologous chromosomes 
(translocation) and gene conversion. Thiagalingam et al (2001) 
investigated likely mechanisms of LOH. The team examined the five 
chromosomes most often lost in CRC using 88 markers and FISH in 
62 CRC cell lines which were microsatellite stable. Mechanisms of 
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loss were chromosome specific. Some chromosomes displayed 
complete loss as might be predicted by mitotic non-disjunction. 
However, more than half of the losses were associated with losses of 
part of the chromosome rather than the whole chromosome. These 
losses were largely due to structural alterations rather than mitotic 
recombination, break-induced replication or gene conversion.  
Haigis et al (2002, 2004) described several different possible 
mechanisms mediating functional loss of APC/Apc: mutation, non-
disjunction, homologous somatic recombination and epigenetic 
silencing. Using a mouse model they demonstrated that loss of Apc 
function could occur by LOH through somatic recombination between 
homologs. Robertsonian translocation RB(7.18)9Lub(Rb9) 
suppressed the multiplicity of adenomas in a mouse model. Their 
evidence showed that homologous recombination was the main 
pathway for LOH in adenomas in B6 min mice. 
Tischfield and Shao (2003) in a commentary of the above paper 
wrote that homologous recombination was a key process in the 
initiation of cancer. It is a general mechanism that provides genomic 
sequence integrity in the repair of double strand breaks and rescues 
stalled DNA-replication forks. But when mitotic recombination occurs 
between homologs one of which has a mutation in a tumour 
suppressor allele the normal allelic sequence may be lost resulting in 
homozygosity for the mutant allele. Mitotic recombination seems to 
be modulated by genetic background and the degree of homology 
between homologous chromosome pairs. Regional proximity of 
homologous chromosome regions is required for the process. One 
might expect that any feature of somatic nuclear architecture that 
increases or decreases the interphase proximity of homologs is likely 
to affect the frequency of LOH due to mitotic recombination.  
 
Gaasenbeek et al (2006) investigated colorectal cancer cell lines 
using array-comparative genomic hybridization (CGH) for copy 
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number changes and single-copy number polymorphism (SNP) 
microarrays for allelic  loss (LOH). Many array based CGH changes 
were not found by LOH because they did not cause true reduction-to-
homozygosity. Conversely, many regions of SNP-LOH occurred in 
the absence of copy number change, comprising an average per cell 
line of 2 chromosomes with complete LOH; 1-2 terminal regions of 
LOH (mitotic recombination); and 1 interstitial region of LOH. 
Microsatellite unstable (MSI+) lines infrequently showed 
gains/deletions or whole-chromosome LOH, but their near-diploid 
karyotypes concealed mitotic recombination frequencies similar to 
those of MSI- lines. These data suggest that CIN is not synonymous 
with copy number change and some cancers have a specific 
tendency to whole-chromosome deletion and regain or to mitotic 
recombination.  
 
An enhanced rate of mitotic recombination is seen in hereditary 
syndromes like Bloom’s, Fanconi anaemia and Werner’s syndrome. 
The pattern of chromosome instability in Bloom’s syndrome is 
characterized by sister-chromatid exchange and homologous 
chromatid interchanges reflected in a gain of homozygosity for 
polymorphic loci. The genes responsible for these syndromes have in 
part been cloned and protein products of both BLM and WRN genes 
are DNA helicases. However these patients do not seem to develop 
bowel cancer.  
 
In summary gross aneuploidy and/or polyploidy does not seem to be 
a common early event in tumourigenesis. It has been proposed that a 
two step model for aneuploidy might exist in which early instability 
does not result in aneuploidy directly but results in mutations in 
genes that then result in aneuploidy (Jones et al 2004).  LOH is 
detectable in early lesions and a process resulting in supranormal 
levels of LOH at an early stage might be seen as a potential initiating 
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factor. Homologous recombination seems the most attractive 
explanation for this. However the mechanisms for early increases in 
homologous recombination remain obscure.  
1.2.4 APC and CIN 
APC mutation is widely considered the initial event in a large 
proportion of colorectal cancers and there is evidence relating this to 
CIN. 
In relation to APC as a cause of CIN Fodde et al (2001) examined 
mouse embryonic cells homozygous for Min or Apc1638T alleles and 
showed that mutant ES cells displayed extensive chromosome and 
spindle aberrations. APC accumulated at kinetochores during 
mitosis. Apc mutant cells formed mitotic spindles with microtubules 
that inefficiently connected to kinetochores. They concluded that loss 
of Apc sequences that lay C-terminal to the β-catenin regulatory 
domain contributed to CIN in CRC. 
Kaplan et al (2001) showed that APC bound to and stabilized 
microtubules in vivo and in vitro, localized to clusters at the ends of 
microtubules near the plasma membrane of interphase cells and was 
an important regulator of cytoskeleton function. They showed that 
cells carrying a truncated APC gene were defective for chromosomal 
segregation in vitro. During mitosis APC localized to the end of 
microtubules imbedded in kinetochores and formed a complex with 
the checkpoint proteins BuB1 and BuB3. In vitro, APC was a high 
affinity substrate for BuB kinases. They suggested that truncations in 
the APC that eliminate microtubule binding may contribute to 
chromosomal instability. 
However this in vitro evidence is at odds with what is seen in vivo, 
with both Sieber (2002) and Giaretti (2004) failing to find evidence for 
aneuploidy in all cancers with truncating APC mutations. Those that 
did demonstrate aneuploidy often showed a near diploid DNA index 
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whereas in the in vitro experiments detailed above the CIN seen was 
often of a polypoid kind usually, tetraploid. Further Giaretti found that 
the type of APC mutation most likely to be associated with 
aneuploidy caused less loss of β-catenin binding and degradation 
sites when compared with mutations not associated with aneuploidy. 
Both types of mutations led to loss of the EB1 binding sites. EB1 
proteins mediate the interaction of APC proteins with kinetochores. 
They concluded that the differential loss of β-catenin binding and 
degradation sites appeared to affect CIN indirectly probably by 
disregulating apoptosis and survival.  
More recently Tighe et al (2004) expressed N-terminal APC 
fragments in HCT-116 cells (a diploid cell line with 2 wild-type APC 
alleles) in an attempt to prove APC mutation could initiate CIN. Cells 
expressing N-APC mutants exited mitosis prematurely in the 
presence of spindle toxins consistent with a spindle checkpoint 
defect. Also N-APC cells showed enhanced survival following 
prolonged spindle damage. The N-APC survivors frequently 
contained dicentric chromosomes and went on to become highly 
aneuploid. These observations suggested that truncating mutations 
of APC can exert dominant effects which could initiate CIN. The APC 
mutation not only compromised tumour suppressor function but may 
also have oncogenic properties. The initial mutation may act as a 
‘double whammy’ destabilising the genome and setting the stage for 
deregulated proliferation following the loss of the second APC allele. 
Dikovskaya et al (2004) showed that depletion of APC from cryostatic 
factor Xenopus extracts led to a decrease in microtubule density and 
changes in tubulin distribution in spindles and asters formed in such 
extracts. Addition of full length protein to a large N-terminally 
depleted fragment or APC depleted extracts restored normal spindle 
morphology. They suggested that APC was important for 
centrosomally driven spindle formation. Lack of microtubule binding 
may lead to mis-segregation of chromosomes. 
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1.2.5 Mechanisms of CIN 
 Gollin (2005) in a review article described mechanisms leading to 
chromosomal instability. Structural chromosomal instability frequently 
results from breakage-fusion-bridge (BFB) cycles. A chromatid break 
occurs exposing an unprotected chromosomal end which after 
replication is thought to fuse with either another broken chromatid or 
its sister chromatid to produce a dicentric chromosome. During the 
anaphase stage of mitosis the two chromosomes are pulled to 
opposite poles forming a bridge that breaks resulting in more 
unprotected chromosomal ends and thus the cycle continues. The 
basis of these cycles is unclear.  
Aberrations in the processes of chromosome segregation also lead 
to aneuploidy. Several factors can result in such instability, including 
abnormal kinetochore-spindle interactions, premature chromatid 
separation, centrosome amplification, multipolar spindles and 
abnormal cytokinesis.  Gollin et al (2005) showed that chromosomal 
segregation defects (multipolar spindles, lagging chromosomes at 
metaphase and anaphase and anaphase bridging) in cancer cell 
lines are intrinsic heritable traits in the general tumour cell population. 
Centrosomes (Saunders W 2005) are important for normal 
chromosomal segregation and they also play a role in controlling cell 
division including initiating cytokinesis and the entry into S-phase of 
the cell cycle. Centrosome defects were originally proposed to lead 
to aneuploidy and cancer by Boveri in 1914. Centrosome changes 
are strongly linked to aneuploidy and cancer in many studies. Under 
some conditions centrosomal replication can become uncoupled from 
the cell cycle allowing multiple centrosomes to form in a single cell. In 
tumour cell lines such over-replication corresponds to reduced 
activity of the p53 pathway. Centrosomal amplification often 
correlates with increased ploidy which in the absence of p53 
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inactivation leads to apoptosis in cell lines. Many observations link 
DNA damage to changes in centrosome number.  Evidence shows 
that double strand breaks may be the signal that induces the 
centrosomal changes. Spindle multipolarity is strongly correlated to 
anaphase bridges which result in DNA breaks. Centrosome 
amplification could proceed through either over-replication of the 
centrosomes or by a cell division or cytokinesis defect leading to 
amplified centrosome numbers. Examples of over-replication in the 
absence of cytokinesis defects are rare.  
The main impact of centrosome amplification on cancer cells is most 
likely to be the formation of multipolar spindles. Both centrosomal 
multipolarity and centrosome amplification are often seen in tumour 
tissue.  However the number of mitotic cells in such tissue is 
generally low and strong correlations are difficult to make. Additional 
changes in the cell other than centrosomal amplification may be 
necessary to induce spindle multipolarity.  
Several centrosomal proteins have been investigated. One family of 
proteins, the Aurora kinases, regulate centrosome function, bipolar 
spindle assembly, chromosomal segregation and cytokinesis 
(Carmena et al 2003, Meraldi et al 2004, (Katayama et al 2003). 
Aurora A kinases localize to the centrosome from the time that 
centrosomes duplicate until the end of mitosis and to a region of the 
microtubules proximal to the centrosomes during mitosis. Aurora B 
kinases are associated with the proteins Survivin and Inner 
Centromere Protein (INCENP) and localize to heterochromatin early 
in mitosis, the central spindle at anaphase, the cell cortex where the 
contractile ring will form and the midbody during cytokinesis.  Aurora 
C localizes to the centrosome from anaphase to telophase. All are 
over expressed in cancer cells. Aurora A over expression is 
associated with centrosome amplification and multipolar spindles. 
Over expression can be as a result of regulatory alterations or gene 
amplification. The gene AURKA or STK15 is located at 20q13.2-13.3 
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and this region is amplified in many cancers. Amplification of a 
common genetic variant of AURKA has been shown to be associated 
with CRC (Ewart-Toland et al 2003). Aurora A over expression has 
been shown to override spindle assembly checkpoint, resulting in 
arrested mitosis with incomplete cytokinesis leading to 
multinucleation (Anand et al 2003). 
Aurora B is involved in destabilization of improper microtubule 
attachments and also plays a role in maintaining assembly 
checkpoints (Hauf et al 2003). Inhibition of Aurora B results in 
misaligned chromosomes, syntelic attachments of chromosomes to 
the spindle poles (in which both chromatids are attached to the same 
pole), cell division failure and endoreduplication. VX-680 inhibits all 
three kinases and results in an accumulation of cells with ≥4 times 
the normal amount of genomic DNA. It also inhibits cell proliferation 
leading to apoptotic cell death in many tumour types (Harrington et al 
2004). Aurora C is the least well understood member of the group. It 
is essential for mitosis.  
‘Chromosome breakage’ syndromes can lead to chromosomal 
instability. Double strand DNA breaks (DSB) represent one type of 
damage that is usually repaired. Failure of that response can lead to 
genetic alteration and chromosomal instability (Mills et al 2003) and 
neoplastic transformation. The DNA damage response involves the 
sensing of DNA damage followed by transduction of the damage 
signal to a network of cellular pathways from those involved in  the 
cellular survival response, including cell cycle checkpoints, DNA 
repair and stress responses to telomere maintenance, and the 
apoptotic pathway. 
The relationship between the DNA damage response genes and 
chromosomal instability is not clear. Haploinsufficiency of damage 
response genes has been associated with instability (Bassing et al 
2003). ATR duplication also is shown to result in abnormal 
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centrosome amplification and aneulpoidy. This is the case for several 
other damage response genes (BRAC1 and MRE11A) which are 
reviewed in (Bharadwaj et al 2004). 
O’Hagan et al (2002) hypothesised that telomere based crisis and 
associated breakage-fusion-bridge cycles drive CIN in cancer cells 
and age related epithelial carcinogenesis. It is suggested that 
telomeres may be the connecting factor between mitotic instability 
and chromosome aberrations. Dysfunctional telomeres may be a 
source of mitotic instability as such dysfunction gives rise to a high 
rate of chromosome bridges at anaphase. These bridges can lead to 
structural chromosome rearrangements through chromatin 
fragmentation or to whole-chromosome losses through kinetochore-
spindle detachment.  
Telomerase positive tumours seem to maintain some degree of 
constant genomic flux. Possibly this base line instability may facilitate 
clonal evolution and adaptation to micro-enviromental challenges 
(Gisselsson D 2005). 
It is unusual to find only one type of cell division disturbance in a 
tumour. Either the cell division machinery appears normal or there 
are a plethora of abnormalities. 
Multiple mitoses and anaphase bridging are seen at variable rates 
indicating that there might be a gradual transition from normal bipolar 
mitoses to mitotic figures exhibiting various abnormalities at a high 
frequency. During transition from colorectal adenomas to carcinomas 
in Min mice the anaphase bridging frequencies increase gradually up 
to the stage of high-dysplasia and then decrease again in metastatic 
tumours (Rudolph et al 2001). This model of telomere dysfunction 
and anaphase bridging has the following limitations. Neither telomere 
dysfunction nor anaphase bridging induced in normal cells by 
ionising radiation will produce ongoing genomic instability at levels 
comparable to neoplastic cells. Disruption of DNA damage sensitive 
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checkpoints is necessary to prevent cells from undergoing 
proliferative arrest or apoptosis. A combination of driving factors is 
necessary to produce lasting instability.  
In CRC, mutations of CDC4 (a putative G1-S checkpoint gene) have 
been demonstrated in 10% of CRC. Disruption of CDC4 in stable cell 
lines triggered abnormal chromosome transmission at mitosis and 
aneuploidy. CDC4 mutations can be seen in the adenoma stage 
before telomere dysfunction. A study by Rajagopalan et al (2004) has 
shown that mutational inactivation of human CDC4 and consequent 
up regulation of Cyclin E occurs at an early stage in colorectal cancer 
and is an important cause of chromosomal instability in these 
tumours. We (Kemp Z 2005), however, found that CDC4 mutations 
occurred in a subset of colorectal cancers, but were not predicted to 
cause loss of function and were not associated with CIN. 
 
1.2.6 Genomically stable cancers 
 
Evidence exists for genomically stable cancers. Georgiades et al 
(1999) – using CGH, flow cytometry and MSI with 2 out of 4 markers 
called MSI+ – examined and found a substantial subset of tumours 
with neither microsatellite nor multiple major chromosomal 
abnormalities. Hawkins et al (2001) examined 46 sporadic cancers 
for CIN using flow cytometry and MSI assessed with PCR using 
standard markers. Immunohistochemistry was also preformed for 
P53 expression.  25 (54%) of tumours were aneuploid, 14 (30%) 
were diploid and microsatellite stable and 7 (15%) were diploid and 
MSI+. From our group Jones et al (2004) screened 23 MSI-CIN- 
colorectal cancers for gains and losses using array-based 
comparative genomic hybridization and  compared their findings with 
those from a small set of MSI+CIN+ cancers, and data from MSI-
CIN+ and MSI+CIN- cancers. They found little evidence of any form 
of genomic instability in MSI-CIN- cancers. At the level of the 
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chromosome arm, the MSI-CIN- cancers had significantly fewer 
gains and losses than MSI-CIN+ tumours. The chromosomal-scale 
changes found in MSI-CIN- cancers generally involved the same 
sites as those in MSI-CIN+ tumours, and in both cancer groups, the 
best predictor of a specific change was the total number of such 
changes in that tumour. A few chromosomal-scale changes did, 
however, differ between the MSI-CIN- and MSI-CIN+ pathways. MSI-
CIN- cancers showed: low frequencies of gain of 9p and 19p; 
infrequent loss of 5q and a high frequency of 20p gain. Overall, their 
data suggested that the MSI-CIN- group was heterogeneous, one 
type of MSI-CIN- cancer having few (≤6) chromosomal-scale 
changes and the other with more (≥10) changes resembling MSI-
CIN+ cancers. At the level of individual clones, frequent and/or 
discrete gains or losses were generally located within regions of 
chromosomal-scale changes in both MSI-CIN- and MSI-CIN+ 
cancers, and fewer losses and gains were present in MSI-CIN- than 
MSI-CIN+ tumours. No changes by clone, which were specific to the 
MSI-CIN- cancers, were found.  Their data supported the suggestion 
that some MSI-CIN- carcinomas formed a qualitatively different group 
from the other cancer types, and also suggested that the MSI-CIN- 
group was itself heterogeneous.  
1.2.7 HNPCC and MSI 
Hereditary Non-Polyposis Colorectal Cancer (HNPCC) accounts for 
approximately 2-4% of familial CRC.  In addition to early-onset CRC, 
presenting at a median age of 42, HNPCC patients are also prone to 
the development of tumours in the endometrium, ovary, stomach, 
small bowel, pancreas and ureter (Watson et al 1993).  HNPCC 
patients have germline mutations in one of four DNA mismatch repair 
(MMR) genes, MLH1, MSH2 (together accounting for 70% of cases), 
MSH6 and PMS2 (Fishel et al 1993, Leach et al 1993, Peltomaki et 
al 1993, Bronner et al 1994, Nicolaides et al 1994, Yu et al 1997).  
MSH6 mutations often occur in an atypical subset of HNPCC 
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patients, characterised by a later age of onset and a more frequent 
occurrence of endometrial cancer (Peltomaki et al 2001).  The MMR 
genes function to ensure the correct repair of DNA base pair 
mismatches and insertion-deletion loops arising as a consequence of 
slippage by DNA polymerase during replication (Modrich et al 1991).  
Replication slippage is most likely to occur in regions containing 
nucleotide repeat sequences such as microsatellites and if the 
mismatch repair pathway is impaired these errors will not be 
corrected, resulting in insertion or deletion of nucleotides.  The 
presence of this repair defect is evidenced by microsatellite alleles of 
different lengths and hence is termed a microsatellite instability 
positive (MSI+), or mutator phenotype (Ilyas et al 1999).  Loss of 
mismatch repair does not just affect microsatellites; all nucleotide 
repeat sequences are potential targets and loss of function frameshift 
mutations have been found in cancer associated genes which 
contain nucleotide repeats in their exons.  Thus, through MSI, growth 
homeostasis and normal cell functioning is impaired and tumour 
progression is promoted.  Approximately 10-15% of sporadic 
colorectal tumours are also found to be MSI+ (Peltomaki et al 1995) 
and 95% lack expression of either MLH1 or MSH2; MLH1 is silenced  
by promoter methylation in 95% of these cases (Thibodeau et al 
1998).   
As in CIN+ cancers, mutations in APC and KRAS2 are a frequent 
occurrence in MSI+ cancers (Aaltonen et al 1993). KRAS2 is 
mutated in HNPCC and BRAF in sporadic MSI+ cancers (Deng et al 
2004). The prevalence of P53 mutations is decreased (Grady et al 
2002) and even those MSI+ cancers which do have a P53 mutation, 
which is usually associated with aneuploidy, still maintain their diploid 
karyotype (Eshleman et al 1998).  Mutations in a mononucleotide 
repeat sequence in APC are particularly prevalent in HNPCC 
patients (Huang et al 1996), suggesting that loss of MMR function 
precedes APC mutation, but in sporadic MSI+ cancers, mutations are 
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not concentrated in the mononucleotide repeat, suggesting that loss 
of MMR does not occur until after APC mutation in the sporadic form 
of the disease (Homfray et al 1998).  
 
It appears that the similar pathways may be affected in CIN+ cancers 
as are affected in MSI+ cancers, with deregulation achieved by 
instability of sequence rather than structure.  For instance, frameshift 
mutation in the A10 tract of TGFBR2, resulting in protein truncation, 
is a frequent event in MSI+ cancers, whereas inactivation of SMAD4, 
which function downstream in the TGFβ pathway, occurs in CIN+ 
cancers (Davies et al 2002, Rajagopalan et al 2002, Yuen et al 
2002).  While mutation of p53 occurs at a lower frequency, mutation 
of BAX, which encodes a p53 dependent inducer of apoptosis, is a 
frequent occurrence in MSI+ cancers.  Furthermore, mutation of 
BRAF, encoding a Ras-regulated kinase has been associated with 
MSI+ cancers and is particularly prevalent in cases where KRAS2 
mutations are absent, again implicating abrogation of the same 
pathway but by alternative mechanisms. 
 
1.2.8 Methylator phenotype  
It has been noted that a subset of CRCs, largely sporadic MSI+ 
cancers (Ahuja et al 1997), display a CpG island methylator 
phenotype (CIMP) in which gene inactivation by promoter 
hypermethylation is a common event (Toyota et al 1999, Yamamoto 
et al 2002).  For example, mutations in the MMR genes are rarely 
detected in sporadic MSI+ CRC; rather, hypermethylation of the 
MLH1 promoter region and consequent loss of transcription and 
protein expression appears to be the major mechanism of 
microsatellite instability (Kane et al 1997, Cunningham et al 1998, 
Herman et al 1998, Veigh et al 1998, Wheeler et al 1999, Kuismanen 
et al 2000).  Epigenetic silencing of a range of tumour associated 
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genes has now been identified.  For example, hypermethylation of 
P16 is found in 60% of MSI+ cancers as compared to 22% of CIN+ 
cancers (Ahuja et al 1997); P16 regulates G1 cell cycle progression 
and stabilises P53 by sequestering MDM1.  Furthermore, aberrant 
promoter methylation of P14, an alternatively spliced form of P16, 
has been found to be associated with microsatellite instability and 
also with absence of P53 mutation (Shen et al 2003), providing 
another possible alternative to mutation of P53 in MSI+ cancers.  An 
increased frequency of inactivation by methylation in MSI+ cancers is 
also detected in the cases of Thrombosin-1 (TSP-1), an 
angiogenesis inhibitor (27% vs 0%) and the Insulin Growth Factor II 
(IGFII) (60% vs 6%) (Ahuja et al 1997).  Overall, 60% of MSI+ 
cancers display hypermethylation of two or more gene loci compared 
to only 9% of CIN+ cancers.  
1.2.9 FAP and the APC gene 
We now leave the discussion of genomic instability to consider in 
more detail the gene related basis of colorectal cancer. Familial 
Adenomatous Polyposis (FAP) is an autosomally dominantly 
inherited disease affecting 1 in 8000 individuals, accounting for ~1% 
of CRC and is caused by germline mutations in the Adenomatous 
Polyposis Coli (APC) gene.  FAP patients develop hundreds of 
colorectal adenomatous polyps in the second and third decades of 
life. They may also develop duodenal polyps and multiple 
extraintestinal manifestations. These may be divided into changes of 
ectodermal origin (epidermoid cysts, pilomatrixoma, central nervous 
system tumours and congenital hypertrophy of the retinal pigment 
epithelium), mesodermal origin (desmoids tumours, bone tumours 
and dental malformations) and those of endodermal origin (as well as 
gut lumen adenomas adenomas of the biliary tract, thyroid and 
adrenal cortex, and hepatoblastomas). Patients unless treated have 
a 100% chance of developing CRC (Inherited bowel cancer. Clark S, 
Colorectal Surgery Third edition (2005) Elsevier Saunders). 
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 A mutation in the APC gene can only be identified in 80% of 
individuals. A milder form of FAP- Attenuated FAP also exists in 
which patients demonstrate fewer polyps than in classical FAP. 
Study of FAP has provided useful insights into sporadic CRC since 
mutation of APC is also the earliest detected genetic event in 
sporadic CRC, occurring in up to 80% of cases (Ilyas et al 1999).   
APC is located on chromosome 5q21 and encodes a large, 
multifunctional 312kD protein that participates in several cellular 
processes, such as cell adhesion and migration, signal transduction, 
microtubule assembly and chromosome segregation (Fodde et al 
2001). However the main tumour suppressing function of APC 
resides in its capacity to regulate intracellular β-catenin levels.  
 
β-catenin functions as a WNT pathway transducer and therefore APC 
has a function in controlling this pathway. The majority of APC 
mutations are nonsense or frameshift mutations that result in a 
truncated protein product with abnormal function (Fearnhead et al 
2002). As well as the initial germline APC mutation loss or mutation 
of the second APC allele is necessary for tumorigenesis (Knudsen’s 
two hit hypothesis (Knudson 1996)).The type of germline APC 
mutation in FAP appears to determine the nature of the somatic hit. If 
the germline mutation occurs between codons 1194 and 1392 there 
is a strong selection for allelic loss of APC as the second hit (Lamlun 
et al 1999). If the second hit occurs outside this region the second hit 
is likely to be a mutation in the somatic mutation cluster region.  
 
Phenotypes of FAP can vary according to the location of the inherited 
APC mutation with a particularly severe phenotype seen in those with 
mutation between codons 1250 and 1464, especially at codon 1309, 
(Nagase et al 1992). Attenuated polyposis is attributed to mutations 
at the extreme 5’ or 3’ ends of the gene (Spirio et al 1993). Mutation 
selection appears to favour a sufficient degree of impairment of APC 
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function to allow nuclear accumulation of β-catenin and consequent 
downstream signalling but is selective against complete loss of 
regulation, perhaps because excessive accumulation of β-catenin in 
the nucleus can result in apoptosis (Kim et al 2000).  Approximately 
6% of the Ashkenazi Jewish population carry a germline I1307K 
polymorphism in APC and have approximately twice the risk of 
developing CRC (Laken et al 1997). Lastly, the APC promoter may 
be hypermethylated, leading to loss of transcription.   
 
1.2.10 WNT signalling 
APC functions as a negative regulator of the WNT signalling 
transduction pathway through its ability to control the levels and 
intracellular location of β-catenin, as depicted in Figure 1.1. 
 
 
 
Figure 1.1. The WNT signalling pathway (Fodde et al 2001) a) in the 
absence of WNT signalling β-catenin is targeted for degradation b) in 
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the presence of WNT signalling β-catenin shuttles to the nucleus and 
activates gene expression. 
 
In the absence of WNT signalling, a “destruction complex” 
comprising APC, the scaffolding proteins Axin and Conductin and 
Glycogen synthase kinase 3β (GSK3β)  binds to β-catenin in the 
cytoplasm (Behrens et al 1998, Hart et al 1998, Fagotto et al 1999, 
Kishida et al 1999). GSK3β phosphorylates β-catenin (Ikeda et al 
2000), which allows it to be recognised by an SCF complex with E3-
ubiquitin ligase activity which transfers Ubiquitin to β-catenin, 
labelling it for degradation by the proteasome (Jiang et al 1998, 
Marikawa et al 1998).  Axin may function by facilitating the 
phosphorylation of β-catenin by GSK3β (Hart et al 1998, Ikeda et al 
2000).  
In the presence of WNT the Frizzled receptor is activated, which in 
co-operation with Low-density-lipoprotein-related protein 6 (LRP6), 
leads to the inactivation of GSK3β in the destruction complex.  
GSK3β inactivation is thought to occur via Dishevelled, which can 
activate GBP, an inhibitor of GSK3β.  In addition, it has also been 
suggested that LRP6 may bind and inhibit Axin (Kishida et al 1999).  
Stabilised β-catenin transfers to the nucleus where, in complex with 
the T-cell factor (TCF) family of DNA binding proteins, it activates the 
transcription of TCF-responsive genes (Behrens et al 1996, Molenaar 
et al 1996).  When no WNT signal is present, TCF/LEF are bound 
and sequestered by the Groucho family of transcriptional repressors 
(Roose et al 1998, Brantjes et al 2001).  The TCF/LEF family of 
transcription factors consists of four members: TCF1, LEF1, TCF3 
and TCF4, the latter being the major binding partner of β-catenin in 
the colon.   
When APC is mutated, it loses its ability to bind and inactivate β-
catenin , therefore, β-catenin is constitutively active even in the 
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absence of WNT signalling and free to continue to transactivate its 
target genes, resulting in uncontrolled cell proliferation.   
Additional components of the pathway are still being identified, such 
as the Casein kinases I and II, which are thought to dephosphorylate 
and inactivate Dishevelled (Polakis et al 2000) and the SFRP family, 
which are found to silence WNT signalling by binding the WNT 
proteins and preventing their interaction with the Frizzled receptors 
(Suzuki et al 2002, 2004).  
 
1.2.11 Beta-catenin  
The induction of β-catenin/TCF signalling can induce transcription of 
a range of genes influencing cell fate, proliferation and tumour 
progression.  For example, the first identified transactivation targets 
were MYC (He et al 1998) and CCND1 (Shtutman et al 1999), the 
over-activity of these genes resulting in uncontrolled cell cycle 
progression (Tetsu et al 1999).  In addition the expression of AF17, a 
fusion partner of MLL in acute leukaemias, which promotes cell cycle 
progression at the G2-M transition, is also induced.  Two components 
of the AP-1 transcription complex, C-JUN and FRA-1 have been 
identified as targets, along with the AP-1 activated urokinase-type 
plasminogen activator receptor (uPAR), which has a predicted role in 
invasive growth and metastasis formation (Mann et al 1999).  Genes 
which code for the multidrug resistance 1 protein (MDR1), which 
promotes tumorigenesis by suppressing programmed cell death 
(Yamada et al 2000) and WISP-1, which can attenuate P53 mediated 
apoptosis in response to DNA damage (Xu et al 2000), are also 
downstream targets of β-catenin/TCF signalling.  In addition, 
increased expression of the genes ENC1, MET, CD44, MMP-7 and 
the γ2 chain of Laminin-5 have been demonstrated in response to β-
catenin induction.  ENC1 encodes the ectodermal-neural-cortex 1 
protein, which can inhibit differentiation through reorganisation of the 
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actin cytoskeleton (Fujita et al 2001); the receptor tyrosine kinase 
MET is a regulator of cell growth, motility and survival through its 
ligand HGF and a crucial player in tumour invasion and metastasis 
(Rong  et al 1994, Boon et al. 2002); CD44 promotes MET signalling 
(Mann et al 1999); the matrix metalloproteinase matrilysin MMP-7 
functions in the breakdown of the extracellular matrix (Brabletz et al 
1999, Crawford et al 1999) and the γ2 chain of Laminin-5 induces 
epithelial cell migration (Hlubek et al 2001). 
   
In addition to its role as a transactivator of transcription, β-catenin is 
an essential component of adherins junctions, which tightly seal the 
space between epithelial cells.  β-catenin links the cell adhesion 
protein E-cadherin to α-catenin and the actin cytoskeleton (Kemler et 
al 1993).  The activity of E-cadherin can affect cell migration and 
morphogenesis and reduced expression levels have been noted in 
CRC (Ilyas  et al 1997).  Thus, through β-catenin, APC can also 
modulate intercellular adhesion.  
 
It is thought that the role of APC as a negative regulator of the WNT 
signalling pathway constitutes its major function as a tumour 
suppressor.  This is supported by the fact that ~50% of CRCs with 
wild type APC contain activating mutations in β-catenin (Morin et al 
1997, Sparks et al 1998).  Most β-catenin mutations affect the 
GSK3β phosphorylation sites and thus provide resistance to 
degradation (Morin et al 1997, Polakis et al 1999).  However, 
adenomas containing β-catenin mutations are not as likely to 
progress to carcinomas as those with mutant APC, suggesting that 
APC and β-catenin mutations are not functionally equivalent and that 
APC is likely to have other tumour suppressor functions (Samowitz et 
al 1999).  For example, in addition to the regulation of β-catenin, it 
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has been demonstrated that γ-catenin, which can also function as an 
oncogene, is a target of APC regulation.  β- and γ-catenin have 
analogous structures and functions and it was found that γ-catenin, in 
co-operation with TCF/LEF factors, activates C-MYC expression 
more strongly than β-catenin (Kolligs et al 2000).  Thus, γ-catenin 
provides an additional route by which the impairment of APC function 
results in the deregulation of WNT signalling. 
 
 
1.2.12  KRAS2, SMAD 2, SMAD4, p53  
In addition to APC, mutations are also frequently found in the KRAS2 
oncogene, located on chromosome 12p.  KRAS2 couples growth 
factors to the MAP kinase signal transduction pathway, promoting 
cell proliferation.  Gain of function mutations are found in up to 50% 
of sporadic CRCs and in synergism with mutant APC, KRAS2 is 
thought to promote tumour progression (Forrester et al 1987, Bos et 
al 1988).  
Loss of heterozygosity (LOH) of chromosome 18q and in particularly 
18q21-qtel is also a frequent event in CRC, occurring in 
approximately 70% of cases (Thiagalingam  et al 1996).  However, 
the incidence of LOH of 18q is only ~10% in early adenomas 
suggesting the importance of this event at later stages of cancer 
progression (Vogelstein et al 1988).  SMAD2 and SMAD4, two 
members of the TGF-β signal transduction pathway, which has a 
pronounced growth inhibitory effect in the colon, map to this region 
and mutations in these genes have been found in 16% (SMAD4) 
(Takagi et al 1996) and 5% (SMAD2) (Takenoshita et al 1998) of 
CRC.   
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The transcription factor p53, located on chromosome 17p, is involved 
in maintaining genomic stability and has been called the “guardian of 
the genome” (Lane et al 1993) due to its role in control of the cell 
cycle and apoptosis in response to genotoxic stress.  p53 activates 
target genes such as p21, BAX, and GADD45, stalling DNA 
replication while lesions in the DNA are repaired or, if the degree of 
damage is severe, inducing apoptosis (Somasundaram et al 2000).  
p53 also activates the expression of MDM2, which targets p53 for 
ubiquinylation and degradation in a negative feedback loop (May et 
al 1999).  Mutations in P53 have been found in up to 70% of sporadic 
CRC, however mutations are rarely found in benign lesions and it 
has been suggested that loss of p53 function is required for tumour 
progression rather than initiation (Vogelstein et al 1988, Rodrigues et 
al 1990).   
 
 
 
1.3    Copy number changes  
The maintenance of normal cell growth depends upon the fine 
balance of expression of growth promoting and growth suppressing 
genes.  In cancer, growth promoting genes, or “oncogenes”, can 
become over-expressed through mutation or an increase in number, 
leading to increased cell proliferation.  Alternatively, a decrease in 
expression of growth suppressing genes can also lead to 
inappropriate cell growth, or a reduction in cell death, such genes 
being termed “tumour suppressors” (Kinzler et al 1997).  While the 
over-activity of one copy of an oncogene is sufficient to disrupt the 
homeostatic balance, loss of both copies of a growth suppressing 
gene is necessary to alter the growth rate.  Inactivation of tumour 
suppressor genes commonly follows Knudson’s “two-hit” hypothesis 
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(Knudson 1996); for instance, by the deletion of one allele and 
inactivation of the other by mutation or promoter hypermethylation. 
The accumulation of multiple gene alterations results in the 
progressive change from normal to uncontrolled growth, malignancy, 
invasion into the surrounding tissue and metastasis. 
One way in which the activity of oncogenes and tumour suppressors 
can be disrupted is by alterations in DNA copy number, ranging from 
gain or loss of entire chromosomes to amplification or deletion of 
discrete sections of DNA (Albertson et al 2003).  An increase in the 
number of copies of a region of the genome can lead to increased 
expression of the genes contained within the region; conversely, 
deletion can lead to reduction or loss of expression of genes located 
within the region of loss (Sawyer W 1983).  Haploinsufficency 
describes the position when one copy of a dosage sensitive gene 
has been lost and such loss leads to phenotypic effects; this is to say 
that the expression products of a single allele are not sufficient for 
normal function. Not all loss of a single allele will lead to this and 
therefore not all genes are haploinsufficient. Dominant loss of 
function mutations are the result of mutations in haploinsufficient 
genes. Parallel measurement of DNA copy number and mRNA 
expression levels in breast tumours has revealed that 62% of genes 
mapping to regions of amplification show elevated expression levels 
and that, on average, a 2-fold change in copy number is associated 
with a 1.5 fold change in mRNA levels (Pollack et al 2002).  For 
example, in colorectal cancer, gain of chromosome 17q has been 
found to correlate with over-expression of the epidermal growth 
factor receptor (ERBB2) (Knosel et al 2002).  The importance of 
deletions in tumour genomes has also been shown, for instance in 
the inactivation of tumour suppressor genes such as PTEN in 
prostate cancer (Vogel F 1979).  Furthermore, the identification of 
copy number changes has directly led to the discovery of genes 
important in tumorigenesis such as the retinoblastoma susceptibility 
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gene (RB1), which was identified as a consequence of its location 
within a region of loss on chromosome 13q14 (211-213). Overall, 
however, the functional significance of copy number changes without 
amplification, homozygous deletion, mutation or methylation are 
unknown.  
 
1.3.1 Comparative Genomic Hybridisation 
In terms of measuring genomic instability a number of techniques 
exist. Detection of LOH using probes at specific loci will reveal LOH 
but says nothing about the genesis of that LOH which may, as we 
have seen, be due to chromosomal loss, part chromosomal loss of 
chromosomal loss and replication. FACS will reveal gross alteration 
in the amount of DNA while revealing nothing of the site of that 
change within the genome. The identification of copy number 
changes at pre-defined loci has historically been achieved by 
Fluorescent In Situ Hybridisation (FISH), using specific DNA probes 
of known chromosomal location hybridised to metaphase 
chromosomes.  For example, amplification of CCND1 at 
chromosome 11q13, detected by FISH, is associated with metastasis 
and reduced survival in squamous cell carcinoma of the head and 
neck (Alavi et al 1999).  However, the development of the technique 
of Comparative Genomic Hybridisation (CGH) (Kallioniemi et al 
1992)  has enabled screening for copy number changes on a 
genome wide scale without the need for metaphase tumour 
chromosomes, which are difficult to obtain in large numbers, or prior 
knowledge of specific regions of interest.  In CGH, genomic DNA 
from a tumour sample and a normal control are labelled with two 
different fluorochromes and co-hybridised to normal metaphase 
chromosome spreads.  The differences in tumour and control 
fluorescence intensities along each reference chromosome are 
reflections of the copy number status of the corresponding 
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sequences in the tumour genome.  If a region is present in equal 
copy number in the normal and tumour genomes, an equal 
contribution from each fluorochrome is seen, however if additional or 
fewer copies of a region are present in the tumour genome, this will 
be reflected in an increased or decreased ratio of fluorescence signal 
from the tumour DNA compared to the normal control.   
CGH investigations of tumour genomes have led to the identification 
of genes important in the development and progression of cancer 
(Lichter et al 2000).  For example, CGH studies in patients with 
Peutz-Jeghers syndrome, which confers an increased risk of 
gastrointestinal tumours, resulted in the localisation of a susceptibility 
locus to chromosome 19p13.3 and the consequent identification of 
the STH11 tumour suppressor gene (Hemminki et al 1998).  In 
addition, a CGH study of oesophageal cancer identified chromosome 
9p23-p24 as a common region of amplification, leading to the cloning 
of a novel oncogene, GASC1, which encodes a transcriptional 
regulator involved in chromatin remodelling (Yang et al 2000).   
 
1.3.2 Array Comparative Genomic Hybridisation 
A major disadvantage of conventional CGH is the limited resolution, 
which at its best is approximately 3-5Mb (Kirchhoff et al. 2001). Thus, 
any unbalanced region detected by conventional CGH is likely to 
contain many potential candidate genes for the pathogenesis of the 
disease.  In matrix (Solinas-Toldo et al. 1997) or array (Pinkel et al. 
1998) CGH, large insert clones (BACs, PACs and cosmids) spotted 
onto glass slides are used as the hybridisation target in the place of 
metaphase chromosomes.  In this way, resolution can be greatly 
improved and is determined by the insert size of the clones and the 
density with which they are selected from the genome.  More recent 
developments include platforms that use smaller clones and 
oligonucleotides (Dutt et al, 2007). 
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The use of genomic clones for array construction is not 
straightforward as large insert clones produce a low DNA yield, 
making extraction of sufficient quantities of DNA labour intensive.  
Therefore, strategies have been developed to amplify small amounts 
of purified clone DNA, to give a reliable representation of the 
template DNA sequence and produce high quantities of DNA for 
spotting.  Firstly, ligation-mediated PCR, which utilises a frequently 
cutting restriction enzyme (producing fragments of 200bp to 2kb) and 
ligation of a universal oligonucleotide adaptor to provide a priming 
site for PCR amplification, was used to generate arrays and 
accurately detect copy number changes (Pinkel et al 1998).  The use 
of cDNA arrays, developed for the analysis of gene expression, has 
also been demonstrated for the investigation of genomic copy 
number changes (Pollack et al 1999).  This approach allows the 
parallel analysis of copy number and expression levels, but analysis 
is limited to well characterised genes, excluding regulatory elements 
and as yet unidentified transcripts.  In addition, while this type of 
array can identify high level copy number changes, low level changes 
are difficult to reliably detect.   
Array CGH on a genome-wide scale was first demonstrated with the 
assembly of a genomic microarray comprising  ~2400 BAC clones, 
providing an average resolution of approximately 1.4Mb and enabling 
the reliable detection of copy number changes, ranging from single 
copy losses to homozygous deletions (Snijders et al 2001).   
The identification of copy number changes by array CGH has been 
used to investigate genomic imbalances present in a variety of 
cancers.  For example, clustering of copy number changes has 
enabled the successful diagnosis of different types of renal cell 
cancer (Wilhelm et al 2002), discrimination between liposarcoma 
subtypes (Fritz et al 2002) and has been used to distinguish gastric 
cancer patients with a high risk of lymph node metastasis and 
consequently a decreased likelihood of survival (Weiss et al 2003).  
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In addition, copy number changes containing genes which may be of 
relevance to the pathogenesis of the disease have been identified by 
array CGH such as gains of chromosome 12q13-q15, including 
MDM2, in pulmonary artery intimal sarcomas (Zhao et al 2002), 
chromosome 3q22-q26, containing PIK3CA, in non-small cell lung 
cancer (Massion et al 2002) and loss of 10q23.2 and PTEN in 
bladder cancer (Hurst et al 2004).  The capability of the technique in 
providing even higher resolution mapping of variation in copy number 
has been demonstrated in the analysis of breast tumours (Albertson 
et al 2000).  A previously reported 2Mb region of copy number gain 
on chromosome 20q13.2 was analysed using an array of overlapping 
large insert clones covering the region.  Two distinct regions of 
amplification (of ~50kb) were resolved, centred upon two potential 
oncogenes, ZNF217 and CYP24.  Thus, the improved resolution of 
array CGH enables the fine structure of copy number aberrations to 
be resolved and can identify potential candidate genes, likely to be 
directly involved in the development of the tumour.   
However, two problems in the analysis of copy number change have 
become apparent (Freeman et al 2006). One is the appreciation that 
copy number change is a feature of normal individuals who are 
essentially healthy and show no obvious genetic disorders. These 
changes represent germline copy number variation.  The second is 
that different allelic dosages may produce phenotypic effects and that 
array CGH measures the total number of alleles and cannot 
distinguish between copy number changes of different alleles of the 
same gene. Further in some cases where copy number change is 
observed modification of the phenotypic effects of that dosage 
change by changes at other genomic sites may mean that such 
dosage change will not be consistent phenotypically across all 
individuals in whom such genomic change is observed. Efforts have 
been made to document common sites of copy number variation in 
normal individuals and also to develop techniques which allow the 
assessment of individual allelic copy number change. 
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An important consideration in the analysis of cancer material by array 
CGH is that often only limited amounts of DNA are available for 
analysis.  However, it has been demonstrated recently that, using a 
modified ligation-mediated PCR protocol and labelling the DNA using 
two nucleotides conjugated to the same fluorophore (rather than the 
traditional one), single copy number changes can be detected with 
only 1ng of genomic DNA as starting material.  In addition, a 
remaining limitation in the use of genomic clones for array 
construction is that the complete sequence of the clone insert can 
contain common repetitive elements such as Alu and LINE repeats 
and regions of homology to other parts of the genome, potentially 
leading to difficulty in the interpretation of array data (Buckley et al 
2002, Fiegler et al 2003).  Recently, arrays have been developed 
which allow the pre-selection of the exact sequence which is spotted 
on the array by using PCR primers designed to amplify only the 
unique, repeat free sequence present in the clone (Mantripragada et 
al 2003).  This approach is especially useful in the analysis of 
aberrations located in regions rich in low copy repeats and has been 
used to identify deletions at a resolution of 15kb in the Di George 
syndrome region of chromosome 22 (Mantripragada et al 2003).  
Detection of copy number changes using oligonucleotide arrays, 
hybridised with genomic “representations” created by cleavage of the 
genome with restriction enzymes and amplification of the resulting 
fragments, has also been demonstrated (Lucito et al 2003, Bignell et 
al 2004).  Lucito et al(2003) employed ROMA (representational 
oligonucleotide microarray analysis) methodology using an array of 
70mer oligonucleotides, giving an average genome-wide resolution 
of ~30Kb, while Bignell et al (2004) utilised oligonucleotide arrays 
originally designed to detect single nucleotide polymorphisms 
(SNPs), allowing the parallel identification of copy number changes 
and loss of heterozygosity (LOH) in cancer genomes.  Genomic 
microarrays have also been used in the analysis of breakpoints of 
aberrant chromosomes (Fiegler et al 2003).   
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Various commercially available oligonucleotide array CGH (oaCGH) 
platforms exist (Ylstra et al 2006). Affymetrix is a commercial oaCGH 
platform, which contains short 25mer oligonucleotides photo-
lithograhically synthesized on the arrays (http://www.affymetrix.com/). 
These are single channel arrays, which means that only test DNA 
needs to be labelled and hybridized. Another commercial oaCGH 
platform was introduced by Agilent Technologies 
(http://www.agilent.com/). They evaluated their original expression 
arrays for this purpose as well as arrays designed specifically for 
aCGH, which include oligonucleotides covering intergenic regions. 
Both Agilent array platforms consist of 60mer oligonucleotides. The 
labelling protocol is similar to the one used for the cDNA arrays and 
requires 1 mg of input DNA which hampers the use of small clinical 
samples. To overcome this problem, a PCR amplification procedure 
was developed allowing as little as 10 ng of input DNA. A third 
oligonucleotide platform offered commercially is by NimbleGen 
(http://www.nimblegen.com/). They provide arrays containing 385 K 
oligonucleotides photolithograhically synthesized on the array. The 
array production is extremely flexible such that each array produced 
can have a different set of oligonucleotides on it.  
1.4  Prognosis in colorectal cancer. 
Colon cancer is staged pathologically on the basis of the extent of 
invasion of the primary cancer and the metastatic spread to lymph 
nodes or distant organs. The Dukes classification is commonly used 
to describe the stage of colorectal cancers. A Dukes B cancer 
describes one that has invaded through the muscularis propria of the 
bowel wall but shows no evidence of lymph node involvement or 
metastatic spread. 25-30% of Dukes B patients are expected to 
develop tumour relapse. It would be desirable to identify at the time 
of treatment which cancers will progress and target adjuvant 
treatment at this group sparing patients from adjuvant treatment 
whose cancers are unlikely to progress.  
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In a consensus statement from the College of American Pathologists 
in 1999 (Compton et al 2000) prognostic factors for colorectal cancer 
were presented as Categories I-IV according to strength of evidence. 
Category I factors were the local extent of tumour assessed 
pathologically; regional lymph node metastasis; blood and lymphatic 
vessel invasion; residual tumour following surgery with curative intent 
and preoperative carcinoembryonic antigen (CEA) elevation. 
Category IIA factors were tumour grade; radial margin status; and 
residual tumour in the specimen following neoadjuvant therapy. 
Category IIB factors were histologic type; histologic features 
associated with microsatellite instability (MSI) (host lymphoid 
response, and medullary or mucinous type); high degree of MSI; loss 
of heterozygosity (LOH) of 18q; tumour border configuration. 
Category III factors were DNA content; all other molecular markers 
except LOH of 18q and MSI-H; perineural invasion; microvessel 
density; tumour associated proteins or carbohydrates; peritumoural 
fibrosis; peritumoural inflammatory response; focal neuroendocrine 
differentiation; nuclear organising regions and proliferation indices. 
Category IV factors were those shown to have no relation to 
prognosis and were tumour size and gross tumour configuration. It 
may be seen that the highest placed molecular markers (LOH 18q 
and MSI-H) ranked below the standard pathological stage in this 
hierarchy. 
1.4.1 Clinicopathological factors 
The gold standard of prognostication remains clinicopathological 
stage (Maughan et al 2002). This is to say invasion of the tumour 
through the bowel wall, peritoneal involvement, the presence of 
lymph node involvement or distant spread of cancer. 
Ratto et al (1998) reviewed the literature relating various 
clinicopathological variables to outcome. Patient gender was 
extensively evaluated (Wied et al 1985, Fielding et al 1986, Scott et 
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al 1987, Shepherd et al 1989, Hermanek  et al 1989, Albe et al 1990, 
Karenaga et al 1991, Garcia-Peche et al 1991, Ponz de Leon et al 
1992, Lasser  et al 1993, Hermanek et al 1994, Deans et al 1994, 
Ikeda et al 1994, Crucutti et al 1991), in the majority of studies, it was 
of no significance in predicting survival independently of other 
factors. In only 4 of 18 studies did patient gender reach statistical 
significance. In three of these studies (Chapuis et al 1985, Griffin et 
al 1987, Newland et al 1994), prognosis was better in females than in 
males, and in the fourth study (Schmitzd-Moormann et al 1987), the 
prognosis was not specified. Gender was found to be significantly 
related to survival in the groups own patients showing a better 
prognosis for females.  
Considering patient age results are more discordant. In 10 of 17 
studies (Fielding et al 1986, Hermanek et al 1989, Albe et al 1990, 
Karenaga et al 1991, Garcia-Peche et al 1991, Ponz de Leon et al 
1992, Ikeda et al 1994, Crucitti et al 1991, Wiggers et al 1988, 
Laurent-Puig et al 1992) when this parameter was evaluated, it was 
not found to be an independent prognostic variable. In 6 studies it 
was found to be of importance (Wied et al 1985, Scott et al 1987, 
Lasser et al 1993, Chapuis et al 1985, Griffin et al 1987, Newland et 
al 1994). 
Most of the older studies documented a worse five year survival rate 
for patients with rectosigmoid or rectal cancers than for those with 
tumours located elsewhere (Spratt et al 1967, Godwin et al 1975, 
Copeland et al 1968, Wotmark et al 1983, Dwight et al 1969).  
However, a large amount of more recent evidence from multivariate 
analyses (Fielding et al 1986, Scott et al 1987, Shepherd et al 1989, 
Albe et al 1990, Karenaga et al 1991, Garcia-Peche et al 1991, Ponz 
de Leon et al 1992, Lasser  et al 1993, Hermanek et al 1994, Deans 
et al 1994, Ikeda et al 1994, Crucutti et al 1991, Chapuis et al 1985, 
Griffin et al 1987, Schmitzd-Moormann et al 1987, Wiggers et al 
1988, Laurent-Puig et al 1992, Steinberg et al 1986) suggests no 
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significant influence of tumour site on long-term outcome. In only 3 of 
21 reports was location of the tumour found to be a prognostic factor; 
2 of these reports (Hermanek et al 1989, Fredman et al 1984) 
considered rectal cancer exclusively, reporting a decreased survival 
rate in lower-third rectal locations. In the third study, (Newland et al 
1994) colonic localization of tumours had a better prognosis than 
rectal.  
A large number of studies suggest that tumour stage, based on 
intramural spread, lymph node involvement, and presence of distant 
metastases, is the most important independent prognostic factor 
(Scott et al 1987, Hermanek et al 1989, Albe et al 1990, Ponz de 
Leon et al 1992, Hermanek et al 1994, Deans et al 1994, Crucitti et al 
1991, Chapuis et al 1985, Griffin et al 1987, Wiggers et al 1988, 
Laurent-Puig et al 1992). In only 3 of 15 multivariate analyses (Wied 
et al 1985, Korenaga et al 1991, Kohal et al 1989) in which tumour 
stage was considered was it not independently related to outcome. 
However, the elements composing the TNM classification have been 
considered individually only in a few studies analyzing tumour stage 
with conflicting results. Among nine studies in which T stage was 
evaluated it was found to be of prognostic significance in six of them 
(Fielding et al 1986, Hermanek et al 1989, Garcia-Peche et al 1991, 
Newland et al 1994). 
 
Blood vessel invasion, particularly referring to venous vessels, has 
been found to be significantly related to tumour stage and grading 
(Minsky et al 1989, Khankhanien et al 1977, Heald et al 1986) and an 
independent prediction factor in many analyses, performed on 
colonic (Wied et al 1985, Minsky et al 1989) rectal (Freedman et al 
1984, Horn et al 1991) or colorectal tumours (Garcia-Peche et al 
1991, Ikeda et al 1994, Chapuis et al 1985, Newland et al 1994) 
Lymphatic vessel invasion also increases with stage and grade and 
was shown to be of prognostic significance in most analyzed studies 
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(Hermanek et al 1989, Ponz de Leon et al 1992, Minsky et al 1989, 
Michelassi et al 1990) both in colonic and rectal carcinomas.   
The role of tumour differentiation degree in outcome prediction has 
been widely investigated. However, conflicting results have been 
reported, most probably 
because of the complex evaluation  criteria that are not well 
standardized. Among 24 studies included in the multivariate analysis 
to assess the value of tumour grading in outcome prediction, only 10 
studies (Wied et al 1985, Scott et al 1987, Albe et al 1990, Garcia-
Peche et al 1991, Deans et al 1994, Chapuis et al 1985, Griffin et al 
1987, Newland et al 1994, Wiggers et al 1988, Selby et al 1992) 
found it to be an independent prognostic factor. In comparison with 
tumour stage, grading did not add any significant advantage in 
survival prediction. Indeed, when both 
parameters were considered only in one study (Wied et al 1985) was 
grading found to be an independent factor, but stage was not; in four 
studies (Ponz de Leon et al 1992, Crucitti et al 1991, Laurent-Puig et 
al 1992, Quirke et al 1987) stage was independently related to 
outcome, whereas grading was not; in two studies (Karenaga et al 
1991, Kohal et al 1989) neither grading nor stage were prognostic 
factors; and finally, in seven studies (Scott et al 1987, Albe et al 
1990, Deans et al 1994, Chapuis et al 1985, Griffin et al 1987, 
Wiggers et al 1988, Selby et al 1992),  both variables were able to 
predict outcome.  
The Petersen index (Petersen et al 2002) is a prognostic model 
consisting of clinicopathological features which has been shown to 
be of use in relation to survival for patients with Dukes B cancers. 
This model uses tumour perforation, peritoneal involvement, venous 
spread, and surgical margin involvement. Dukes B cancers with none 
of these characteristics had a comparable prognosis to Dukes A 
cancers while the presence of high risk factors reduced the five year 
survival to 49.8%. This index has been independently verified in a 
further study (Morris et al 2007).  
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Other clinical factors have been found to be independent prognostic 
markers. These include presentation type, for example, obstruction 
(Ratto et al 1998), intraoperative factors such as the surgeon and the 
use of total mesorectal excision (MacFarlane et al 1993) and whether 
blood transfusion was required. The quality of clinical care, surgery 
and pathology taken together impacts on survival with the hospital 
the patient is treated in effecting survival (McArdle et al 2002). The 
quality of the surgical specimen, as assessed by circumferential 
involvement and the macroscopic appearance of the specimen 
(Birbeck et al 2002), is an important audit role of the pathologist. 
Such pathology must be carried out to a high standard and the 
pathologist must correctly diagnose nodal involvement (Tepper et al 
2001). 
Clearly in order that novel prognostic factors are correctly assessed 
the quality of the surgical resection, pathological examination and 
general care must be high so that these variables do not unduly 
influence survival and skew survival results.  
 
1.4.2 Genetic factors. 
Many somatic genetic factors have been investigated in relation to 
prognosis, the principle ones of significance being 18q LOH and MSI. 
Prognostic information relating to other genetic factors known to be 
related to CRC is given below. The prognostic data relating to 
aneuploidy, chromosome 5 LOH and MSI is given in more detail later 
in the appropriate discussion sections.  
18q LOH has been associated with poor prognosis. In a systematic 
review and meta-analysis of the relationship between chromosome 
18q genotype, DCC status and colorectal cancer prognosis Popat 
and Houlston (Popat et al 2005) found after reviewing 27 eligible 
studies that 17 studies showed cancers with chromosome 18q loss 
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appear to have a poorer prognosis. However they did note a lack of 
consistent methodology. 
 
It has been previously shown that more than 75 percent of colorectal 
cancers show 17p LOH (Allen et al 2005). The 17p segment that is 
lost contains the tumour suppressor gene P53. A number of studies 
have assessed p53 expression in relation to prognosis and found no 
prognostic role in early stage CRC (Allegra et al 2003, 
Giatromanolaki et al 1999, Soong et al 1997, Bhatavdekar et al 
2001). P53 overexpression demonstrated by immunohistochemistry 
has been related to poor prognosis, but other studies, especially 
those using PCR-SSCP, do not always confirm this relationship 
(Allen et al 2005). Ilyas (Ilyas et al 1996) compared Dukes B cancers 
and found those with recurrence to have 56.9% positive p53 staining 
compared to 53.3% for those cancers not associated with 
recurrence. 
P53 mutation has been associated with poorer survival. Mutations 
which lengthen its half life have been shown to lead to worse 
outcome (Mcleod et al 1999). If both KRAS and P53 mutations are 
found within a tumour these may have an additive effect on reducing 
survival.  
Specific KRAS2 mutations have been shown to be linked to poorer 
survival (Kirsten ras in Colorectal Cancer Collaborative Group 2001). 
The RASCAL I and II meta-analyses examined the importance of 
KRAS2 mutation and found that different gene mutations had 
different effects on survival even if mutations occurred at the same 
site. Recently it has been shown that mutations of codon 12 and 13 
of exon 2 of the gene render a cancer resistant to the anti epidermal 
growth factor receptor drugs Cetuximab and Panitumumab (Plesec et 
al 2009). 
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MSI+ve CRCs may have an improved prognosis (Haydon et al 2002, 
Elsaleh et al 2001). Genes carrying short repetitive sequences tend 
to be mutated in MSI+ tumours: CTNNB1, BAX, TCF4, CDX2, E2F4, 
TGFBR2 and some other mismatch repair genes (Haydon et al 
2002). None of these genes has been investigated for prognostic 
significance.  
Aneuploidy has been shown to be correlated with worse prognosis 
(Barratt et al 2002, Quirke et al 1987, Schutte et al 1987).  
Increased Bcl-2 expression detected by immunohistochemistry may 
be associated with better prognosis (McLeod et al 1999). Studies 
(Ilyas et al 1996, Meterissian et al 2001) have shown a relationship 
between enhanced Bcl-2 expression and improved survival. Ilyas 
(Ilyas et al 1996) found positive Bcl-2 staining in 69% of non-
recurrent Dukes B cancers  and 33% of recurrent cancers (In this 
work 37.5% of >5 year survival patients showed positive Bcl-2 
staining).However, other research is less convincing in terms of this 
relationship (Barratt et al 2002). 
 
 Angiogenesis promoting factor VEGF is over expressed in 50% of 
tumours (Papamichael et al 2001). VEGF+ve tumours may have a 
worse prognosis than VEGF–ve tumours (McLeod et al 1999, 
Papamichael et al 2001).  
E-cadherin expression is lost in tumour cells leading to decreased 
adhesion and facilitating metastasis. A recent study from Lugli et al 
(2007) examined the relationship between E-cadherin and β-catenin 
expression and prognosis in a large number of tumours (1420). For 
MSI- cancers, increased nuclear β-catenin expression and loss of 
membranous E-cadherin were independently associated with higher 
N stage, vascular invasion, and worse survival. Additionally there 
was a relationship between loss of membranous E-cadherin 
expression and higher T stage. Previous research relating β-catenin 
53 
 
to prognosis had been less conclusive (Hao et al 1997, Kobayashi et 
al 2000, Iwamoto et al 2000, Maruyama et al 2000). Factors such as 
small study size, differences in antigen retrieval and staining 
procedures and lack of a standard evaluation system for declaring a 
case as positive or negative for aberrant β-catenin expression have 
probably been responsible for differences in results.  
 
Lytic enzymes such as matrilysin have been seen in increased 
amounts on cDNA arrays (Notterman et al 2001) and matrix 
metalloproteinase (MMP) production is increased in CRCs (McLeod 
et al 1999). These enzymes degrade extracellular matrix allowing 
tumour invasion. The presence of MMP1 is associated with poorer 
prognosis. 
In terms of the sort of changes one might expect to determine by 
CGH, analysis has been done relating LOH at various loci to 
outcome. 18q and 17p have already been discussed. Those patients 
with moderate 20q copy number increase had longer survival 
compared to those without the changes or those who had high 
increase in copy number. Loss of 18q in conjunction with 8p may be 
a poor prognostic sign (Gerdes et al 1995). 1p has been examined in 
three further studies (Gerdes et al 1995, De Angelis et al 2001, 
Ogunbiyi et al 1997). Two of these studies showed that loss of 1p 
was associated with shorter survival time. The third study found no 
such relationship. De Angelis et al (2001) showed a relationship 
between deletion of 14q and survival. Al-Mulla et al (2006) also found 
14q loss to be associated with metastatic recurrence additionally 
finding loss of 4p significantly associated with metastatic disease and 
4p and 14q loss jointly to be an independent prognostic indicator on 
multivariate analysis.  Arribas et al (1999) also found 4p 14-16 allelic 
loss to be associated with poor survival. Choi et al (2002) found that 
high levels of LOH in cases without MSI correlated with earlier onset, 
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lymphatic invasion and rectal position whereas lesser levels of 
chromosomal arm involvement were associated with cancers of the 
proximal colon and stage I and II. For stage II cancers high level 
chromosomal loss was a significant predictor survival. 
CGH has been used to examine colorectal cancers with some work 
relating to outcome. De Angelis et al (2001) found that losses of 1p, 
4q, 8p, 14q and 18q and gains of 20q were associated with shorter 
survival times, as were >6 chromosomal aberrations per cancer. 1p 
and 8p loss were independent prognostic markers. Al-Mulla et al 
(2006) found that cancers associated with metastasis exhibited more 
complex genomic aberrations than non-metastasising cancers. Loss 
of 4p was an independent prognostic factor as was loss of arms 8p 
and 18q. Loss of chromosomes 4 and 14q bestowed poorer 
prognosis compared with those with only one of these losses. This 
study used array CGH for a small number of samples. In these two 
studies patients were not stratified for MSI status. This represents a 
flaw in their methodology since MSI + and MSI- differ markedly in 
terms of genomic gains and losses. 
Gene expression array research has been used in relation to 
prognosis. Wang et al (2004) used RNA from 74 patients with Dukes 
B cancer. 31 patients had developed tumour relapse in less than 3 
years and 43 had remained disease free for greater than 3 years. 
Gene expression profiling identified a 23 gene signature that 
predicted recurrence in Dukes B cancers. This was used to predict 
survival in a further 36 patients correctly predicting outcome in 28. 
The markers conferred a 13-fold increase in risk of relapse. 
 
 
1.5    Aims of thesis 
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The primary aim of this thesis was to investigate the use of aCGH in 
prognosis in colorectal cancer by examining differences in aCGH 
results for Dukes B cancers with good and bad outcome, the null 
hypothesis being that there is no difference between the two in terms 
of these types of changes in relation to array CGH. Other test results- 
namely for MSI, APC LOH and ploidy- were also to be compared 
between these two groups.  
A secondary aim was to identify new oncogenes related to CRC. 
A tertiary aim of the thesis was to use aCGH to investigate the timing 
of chromosomal instabitility by using the technique to study genomic 
gains and losses in adenomas. 
At the time of planning this research (2003) no publications existed 
relating array CGH or simple CGH to outcome for Dukes B cancers. 
It was unknown whether copy number change would be linked to 
outcome and no alternative technique existed at this point for 
assessing copy number change over the whole genome in a single 
experiment at high resolution(1 Mb), although results from LOH 
experiments  performed on series of different stage cancers and 
those comparing good and bad outcome cancers, suggested that 
there might be differences between outcome groups in terms of 
these factors.  
Further by analysing small gains of genomic material revealed by 
array CGH and comparing such areas with the human genome map 
it was hoped that it would be possible to determine candidate 
oncogenes of as yet uncertain importance in colorectal cancer and 
further investigate whether such genes exhibited unusual expression 
in cancer tissue with In Situ Hybridisation (ISH) analysis. At the time 
the research was conducted  very little was known about the 
importance of the candidate genes investigated in terms of their 
importance in CRC tumorigenesis. 
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Additionally, to investigate the timing of genomic instability we 
planned to analyse sporadic adenomas with aCGH. As has been 
discussed, the point at which CIN develops in tumorigenesis is a 
subject of debate and at the time of performing this research no 
papers existed that had used array CGH to investigate adenomas. 
Thus, in terms of overview the work took the following course. 
Cancer samples collected at the John Radcliffe Hospital, the Leeds 
General Infirmary and St Mark’s Hospital were used for the work. We 
needed to gather samples from three centres in order to maximise 
the number of Dukes B cancer DNA samples with associated long 
term follow up data. Although a power calculation had suggested a 
need for 45 samples, the power calculation was made on the basis of 
LOH data and we thought it advisable to maximise the amount of 
samples analysed . Dukes B cancer tissue from patients with long 
term follow up data is hard to get and multiple centres were needed 
to increase sample numbers.79 Dukes B cancers were divided along 
survival lines into those from patients with 5 year survival and those 
from patients who died within 5 years of surgery. For these cancers, 
clinicopathological data including age, gender, tumour location, 
lymphovascular invasion, T stage and pathological grade were 
determined. These were related to outcome. All cancers were tested 
for MSI status and APC LOH. These data were compared with 
outcome. The Oxford cancers were also tested for 
aneuploidy/polyploidy using flow cytometry. aCGH experiments were 
conducted on all Dukes B cancers and results given for the whole 
group and the different survival groups. Differences in genomic gains 
and losses between the survival groups were determined.  
Four candidate genes were then selected on the basis of these and 
other aCGH results and ISH experiments undertaken on a tissue 
microarray (composed of a different set of cancers) and the results 
compared with known outcome for the tissue array samples. The 
tissue array was used as it allowed ISH experimentation on a large 
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number of cancers in a single experiment. For clarity I will restate 
that all cancers comprising the tissue array were different to those 
used in the main body of research. 
Lastly aCGH was performed on adenomas and gains and losses for 
that set of tissue recorded. 
 
In terms of summary by chapter: 
Chapter 1 gives the background to the subject of colorectal 
cancer genetics, prognosis in Dukes B cancer and aCGH. 
Chapter 2 outlines methods and materials used in the 
research. 
Chapter 3 outlines sample collection and processing from 
the three centres and relates simple patient and tumour 
characteristics to outcome. 
Chapter 4 describes the experiments allowing the 
classification of the samples in terms of their gross 
genomic stability. 
Chapter 5 describes the aCGH findings and comparison of 
these between different outcome and instability groups. 
Chapter 6 describes the selection on the basis of aCGH 
results of candidate genes and ISH work on these 
candidates. The chapter also describes the use of a tissue 
array comprised of a separate set of cancers to investigate 
possible links between candidate gene expression and 
outcome in this separate cancer group. 
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Chapter 7 describes aCGH experiments on a group of 
adenomas to investigate timing of genomic instability. 
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Chapter 2. 
Methods and materials. 
 
 2.1 DNA extraction from fresh-frozen tissue. 
DNA was extracted from fresh-frozen tissue using the DNEasy Kit 
(Qiagen) according to the manufacturer’s instructions. This method 
permits isolation of 10-30µg of DNA from 25mg of tissue. Briefly, the 
tissue was cut into small pieces, lysed with proteinase K, treated with 
RNAase to degrade RNAs, precipitated with ethanol and added to a 
spin column to bind the DNA. After a series of washes to remove 
protein debris, the DNA was eluted from the column with dH2O. 
2.2 Spectrophotometry 
To assess DNA quantity and quality, aliquots were diluted in dH20 
and analysed by spectrophotometry at 260nm and 280nm using a 
SPECTRAmax PLUS spectrophotometer. As an optical density (OD) 
of 1 at 260nm corresponds to about 50µg/ml double-stranded DNA, 
sample concentrations in µg/ml were calculated as ‘dilution factor x 
50 x OD 260. OD 260/OD 280 ratios were calculated to assess the 
DNA quality. Pure DNA samples have an OD 260/OD 280 ratio of 
1.8. RNA contaminationl increased ratio towards 2.0 while protein 
conyamination decreased the ratio towards 1.4. 
2.3 Polymerase chain reaction 
 
The polymerase chain reaction (PCR) is an in vitro technique for 
DNA synthesis, which allows selective amplification of a specific DNA 
sequence. The reaction requires two oligonucleotide primers, which 
hybridise to opposite strands and flank the target region in the 
template DNA. In addition, the reaction requires the four 
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deoxyribonucleoside triphosphates dATP, dTTP, dGTP and dCTP, 
and a thermostable DNA polymerase. A PCR reaction typically 
consists of 35 cycles, and each cycle has three steps: (i) 
Denaturation of the DNA template, (ii) annealing of the primers to the 
separated template strands, and (iii) extension of the primers by DNA 
polymerase. The first PCR cycle creates two new strands of variable 
length per DNA template, which can act as targets in the second 
cycle. The third cycle produces double-stranded DNA molecules 
which comprise precisely the target region defined by the two 
primers. The following cycles result in an exponential doubling of this 
target fragment which soon becomes the predominant reaction 
product. PCR amplification is not infinite, and the desired fragment 
gradually stops to accumulate. Several factors determine the point at 
which the reaction plateau is reached including the utilisation of 
substrates (dNTPs or primers), the stability of DNA polymerases, and 
the competition for reactants by non-specific products or primer-
dimers. 
 
PCR primers were obtained from public sources using the Primer3 
programme of the Whitehead Institute of Biomedical Research 
(http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_ www.cgi). A 
typical 25µl PCR reaction contained 30-50ng of template DNA, 
0.4pmoles of each primer, 1x Mg2+-free PCR buffer (Promega), 
2mM MgCl2 (Promega), 0.2mM of each dNTP (Amersham) and 1 
unit of PIC Taq DNA polymerase (Cancer Research UK). DNA 
samples were aliquoted into a 96-well plate (ABgene), and a PCR 
master mix was made up with the remaining reaction components. 
The master mix was vortexed and added to the samples. The plate 
was sealed with Thermowell Sealers (Corning) and immediately run 
on a Tetrad PCR Machine (MJ Research). A standard PCR reaction 
consisted of an initial denaturation at 94°C for 5min, 35 cycles of 
94°C for 1min, 55°C for 1min, and 72°C for 1min, and a final 
extension at 72°C for 10min. Depending on the primer pair and target 
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size, variations of these conditions (Mg2+ concentration, additives, 
annealing temperature, extension time) were necessary. Products 
were run on the ABI377 sequencer, and results were analyzed using 
Genotyper software 
 
2.4 Loss of Heterozygosity analysis 
 
For LOH analysis, matched DNA samples from normal colonic 
mucosa and tumour tissue were genotyped at a set of microsatellite 
markers close to the tumour suppressor gene under investigation. 
Microsatellite markers are short tandem repeats of mono-, di-, tri- or 
tetra-nucleotides which are frequently polymorphic in the population. 
The forward primer of each PCR reaction was labelled with a 
fluorochrome (FAM, HEX or TET). The PCR products were run on a 
semi-automated ABI Prism 377XL DNA sequencer (PE-Applied 
Biosystmes) together with GENESCAN-350 TAMRA size marker 
(PE-Applied Biosystems). The results were analysed for allelic loss 
using GENESCAN and GENOTYPER software (PE-Applied 
Biosystems). For heterozygous samples, the area under each allele 
peak was determined, and the ratio of the areas of the two alleles 
was calculated. The LOH value was calculated. The LOH value was 
calculated by dividing the allelic ratio of the normal tissue by the 
allelic ratio of the matched tumur tissue. LOH values ≤ 0.5 or ≥ 2.0 
were scored as allelic loss, assuming that the tumour contained more 
than 50% neoplastic material as confirmed by histopathological 
examination. 
 
2.5    Flow Cytometry  
 
Flow cytometry (FACS) techniques offer a means of assessing the 
amount of DNA contained within the cell nucleus. It can be applied to 
any tissue that can be reduced to a single-cell suspension. After 
disaggregation, the cells are treated with RNase (to degrade RNAs) 
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and stained with a flouresecent dye that binds stoichometrically to 
DNA. As individual cells are passed through a laser beam, dye-
emission can be measured which is proportional to the DNA content. 
Typically, 10,000 or more cells can be analysed in minutes, and the 
results can be expressed as a frequency curve of DNA content. From 
this data estimates of the number of cells with 2C (C=haploid 
genome), intermediate and 4C DNA content can be obtained, 
corresponding to G0/G1, S and G2+M phases of the cell cycle. When 
comparing normal and tumour samples, aneuploidy or polyploidy can 
be identified as extra peaks, provided that more than 5% of 
chromosomal material have been gained or lost (approximately 1 
large or two medium/small sized chromosomes). The ratio of 
medians of G0/G1 peaks of tumour and normal sample is referred to 
as DNA index (DI).  
 
FACS was performed on formalin fixed, paraffin-embedded tissue 
which was prepared by cutting a 50mm section from each tissue 
block, placing it into a histopathology cassette between two sheets of 
3MM filter paper, and dewaxing it in 100% xylene (BDH) overnight. 
The section was rehydrated through an ethanol series (100%, 95%, 
90%, 70%, 50%) and rinsed twice in water. The tissue was removed 
from the slide with a scalpel and digested with (0.5% pepsin (Sigma), 
0.9% NaCl, pH 1.5) for 30 min at 37°C. After centrifugation at 1500 
r.p.m for 5 min at room temperature cells were washed twice in PBS 
before flow cytometric analysis and detection of near-diploid and 
polyploidy cell populations. Following washing with PBS, the cells 
were treated with 40 µg/ml propidium iodide (PI) and 10 µg/ml RNase 
for 30 min at room temperature then analysed on a FACSCalibur 
(Becton Dickinson). 
Cells were excited by the argon laser emitting 488nm. PI 
fluorescence was detected using a 670nm long pass filter. Forward 
and right angle light scatter were used to set gate including all cells, 
but excluding debris. A second gate set on area and width of PI 
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fluorescence were collected in linear mode, and acquisition was 
stopped after 8000 gated events had been acquired. Data were 
analysed for aneuploidy (DNA index or D1) using dedicated Modfit 
software (Verity Software House). The DNA diploid peak was set 
using the normal samples. 
 
2.6     Array Comparative Genomic Hybridisation   
The genesis and function of CGH has been described in the 
introduction.The array construction and hybridisation were performed 
as described by Fiegler et al (2003) and Douglas et al (2004). In 
brief, DNA samples were isolated from 3452 large insert genomic 
clones (BACs, PACs and cosmids), at an average spacing of about 
1Mb throughout the genome, and were amplified using DOP-PCR. 
The DOP-PCR products were subjected to a further amino-linking 
PCR and the products were arrayed onto amino-binding glass slides 
in duplicate. Six Drosophila clones were arrayed in duplicate 
alongside the human clones.  
Test and control DNAs were differentially labelled using Cy-dye 
modified dCTPs (Cy3 and Cy5) (NEN Life Science Products, Boston, 
MA) and a Bioprime Labelling Kit (Invitrogen) with a modified dNTP 
mix.  For array CGH, 450ng of test and reference genomic DNAs 
were labelled. The DNA was added to H2O to give a final volume of 
66µl, 60µl of 2.5x random priming solution was added and the DNA 
denatured at 100°C for 10 minutes.  15µl of 10x dNTP mix (1mM 
dCTP, 2mM dATP, 2mM dGTP, 2mM dTTP in TE buffer), 1.5µl of 1M 
Cy3-dCTP or Cy5-dCTP and 3µl Klenow fragment were added on ice 
and the reaction incubated overnight at 37°C. The reaction was 
terminated by the addition of 15µl stop buffer and unincorporated 
nucleotides were removed using microspin G50 columns 
(Pharmacia).  Three columns per sample were prepared for use by 
vortexing briefly to resuspend the resin, loosening the cap, snapping 
off the bottom closure and centrifuging at 735g for 1 minute whilst 
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placed in a 1.5ml Eppendorf tube.  The column was placed in a fresh 
1.5ml Eppendorf tube and 55µl of the reaction mix was loaded onto 
the resin bed and centrifuged at 735g for two minutes.  Spin through 
from the 3 columns was pooled and 5µl run on a 2.5% agarose gel.   
For the 1Mb array (6cm2), 180µl of Cy3 labeled DNA, 180µl Cy5 
labeled DNA, 135µl human Cot1 DNA (Roche), 54µl of 3M sodium 
acetate pH 5.2 and 1ml 100% ethanol were precipitated together for 
30 minutes at -70°C.  In a separate tube, 80µl Herring sperm DNA 
(10mg/ml Sigma), 135µl Cot1 DNA (Roche), 24µl 3M sodium acetate 
pH 5.2 and 1ml 100% ethanol were precipitated together for 30 
minutes at -70°C.  Both tubes were centrifuged at 7700g for 15 
minutes and the supernatant removed.  Pellets were washed with 
500µl of 80% ethanol, centrifuged at 7700g for 5 minutes and the 
supernatant removed.   
The labeled DNA/Cot1 mix was resuspended in 60µl of hybridisation 
buffer , (50% formamide (Fluka), 10% dextran sulphate (Amersham), 
0.1% Tween 20 (BDH), 2xSSC, [10mM Tris-Cl pH 7.4]), which had 
been prewarmed to 70°C, along with 6µl of yeast tRNA (100µg/ul, 
Invitrogen), to create a hybridisation solution.  The Herring 
sperm/Cot1 mix was resuspended in 160µl of hybridisation buffer to 
create a prehybridisation solution.  Both solutions were denatured at 
70°C for 10 minutes.  
Two layers of rubber cement were placed around the area covered 
by the array on the slide to create a hybridisation well.  The 
prehybridisation solution was applied within the well and the slide 
was agitated to ensure that the entire array was covered with 
prehybridisation solution.  The slide was placed in a humidity 
chamber, which contained 3MM paper (Whatman) saturated with 
2xSSC/40% formamide and incubated for 60 minutes at 37°C whilst 
rocking (5rpm).  The hybridisation solution was incubated at 37°C in 
the dark for 60 minutes.  As much prehybridisation solution as 
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possible was removed from the hybridisation well using a p10 pipette 
and the hybridisation solution was applied to the array.  The slide 
was placed in a second hybridisation chamber, which contained 3MM 
paper (Whatman) saturated with 2xSSC/20% formamide.  The 
chamber was sealed with parafilm and incubated for 48 hours at 
37°C whilst rocking (5rpm). 
The slide was removed from the hybridisation chamber and the 
rubber cement removed with forceps.  The slide was briefly rinsed in 
PBS/0.05% Tween 20 (BDH) and then washed in PBS/0.05% Tween 
20 (BDH) on a rocking platform (70rpm) for 10 minutes at room 
temperature.  The slide was incubated whilst rocking in 50% 
formamide/2xSSC at 42°C for 30 minutes, followed by a second 
wash in fresh PBS/0.05% Tween 20 (BDH) on a rocking platform 
(70rpm) for 10 minutes at room temperature.  The slide was dried by 
centrifugation at 150g for 5 minutes and stored in the dark until 
scanning  
Slides were scanned on an Axon 4000B scanner (Axon Instruments) 
or an Agilent G2565BA scanner (Agilent Technologies).  The photon 
multiplier tube (PMT) levels used for detection were manually (Axon) 
or automatically (Agilent) adjusted and tailored for each array.  
Images were quantified using Genepix 4.0 software (Axon 
instruments) or the “Spot” analysis program. 
Sanger arrays were analysed using an excel spreadsheet, 
proceeding through the following steps. To control for non-specific 
hybridisation signals, the raw Cy3 and Cy5 intensity signals produced 
by each spot on the array were compared to the average Cy3 and 
Cy5 intensity signals produced by the Drosophila spots.  Only spots 
with greater than twice the average Drosophila spot intensity in at 
least one fluorescence channel were accepted for analysis. A raw 
ratio of intensities for each accepted spot was calculated by dividing 
the test intensity by the reference intensity. To adjust for any 
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imbalances in the labelling efficiency or scanning of the 
fluorochromes, raw ratios were normalised by dividing by the median 
raw ratio for all autosomal spots. The median normalised ratio for 
each pair of duplicate spots was calculated and compared to the 
individual ratios reported by each duplicate spot.  If the individual 
ratios deviated by greater than 10% from the median, the spots were 
rejected from further analysis. The final linear ratio for each clone 
was taken as the mean of the normalised ratios of the duplicates 
spots.  This ratio was then converted into a log2 ratio and plotted 
against the mapped position of the clone in the genome. A previously 
constructed excel macro programme provided different presentations 
of the data including plots of the raw data and normalised data both 
for the whole genome and for each chromosome. 
For Wellcome arrays processing of the glycerols, extracting DNA and 
DOP-PCR was conducted in the same way as described by the 
Sanger group 
(http://www.sanger.ac.uk/HGP/methods/cytogenetics/DOPPCR.shtml
). 3452 Sanger clones were used. Processed DNA was spotted onto 
a Corning GAPS 11 Amino-silane coated slide with 3 replicates per 
slide using a Lucidea Array Spotter (GE Healthcare). In terms of 
hybridisation, 1 microgram of cancer DNA and 1 microgram of pooled 
normal female DNA, were used for each hybridisation. These were 
labelled as for the Sanger arrays described above.  
The hybridisation of the Wellcome arrays differed from the method 
used for the Sanger arrays and was as follows. Labelled target DNA 
was confirmed as being in base of an Eppendorf tube and then 
boiled at >95°C for 5 minutes with foil over the top of the tube. The 
Eppendorf tube was transferred to a 37°C hot block, covered with foil 
and left for 55 minutes. The required number of cover slips was 
prepared one at a time: cover slips were removed from 100% EtOH 
using forceps and placed in clean 50ml tubes (Falcon) and the tubes 
placed in a microwave oven for 55 seconds. A hotplate was 
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preheated to 37°C. When there were 15 minutes of DNA heating left 
the CMT hybridisation chamber (Corning 231) was prepared. This 
chamber was washed with water and dust particles removed. The 
chamber and black holding clamps were lightly greased with 
Vaseline. When DNA incubation had 5 minutes to go, the wells at 
each end of chamber were filled with 3.4X SSC. It was also 
necessary to add drops of 3.4X SSC at each end of the chamber 
next to the wells. Then the slides and cover slips were prewarmed by 
resting them on a 37°C hot block. Enough space should be left 
between cover slips for slides to be lowered on to them. The labelled 
target DNA was then removed from the bottom of the Eppendorf tube 
and pipetted either side of the central area of the clean cover slip 
placed at the edge of the hot block. The array slide was carefully 
lowered onto the cover slip so that the arrayed DNAs were in contact 
with the cover slip. The slide was placed in the hybridisation chamber 
and the lid put on the hybridisation chamber which was sealed at the 
sides with clamps. The chamber was placed in a 65°C water bath for 
48 hours. Washing was performed as for the Sanger arrays. 
Wellcome arrays were scanned using an Axon GenePix 4000B 
scanner and data analysed using GenePix Pro 4.1and Microsoft 
Excel. Using the GenePix Pro proceeded as follows. Scanned 
images were opened. The settings for a grid that matched the layout 
of the slide were chosen. A preliminary visual examination of the 
slide was made and features (spots) flagged that were poor or 
absent. Analysis was then performed and the results file saved. This 
output file was then saved as an Excel file and data sorted by 
Chromosome and  ID. To normalise the data a median of the values 
“Ratio of Means (635/532)” for all autosomal clones was calculated. 
First “Ratio of Means (635/532)” values for flagged clones were 
removed from the median calculation data set. The value of “Ratio of 
Means (635/532)” for all clones was divided by the calculated median 
to get a normalised ratio for each clone. The mean and standard 
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deviation were calculated, using the normalised ratios, for each clone 
(mean and SD calculated for the 3 replicates of that clone). If the 
calculated SD was above 0.2 for the 3 replicates, the most outlying 
value of the Normalised ratios was removed. If more than 1 replicate 
was excluded the clone was excluded from further analysis. A graph 
to visualise the result of the hybridisation was then drawn: Average 
Normalised ratios vs. Chromosome (Genomic position). 
Deciding whether a clonal gain or loss is statistically significant has 
been outlined previously by Roylance et al (2006). In this method a 
confidence interval for the variability in fluorescence intensity ratios 
was produced by performing normal versus normal hybridisations. It 
then becomes possible to identify clones differing significantly from a 
ratio of 1. While the method described by Douglas et al (2004) is 
applicable to cell lines derived DNA, the differing proportions of 
normal tissue contaminating cancer tissue mean that no single 
threshold for gain and loss can be applied generally across all 
experiments. For experiments involving tissue derived DNA threshold 
values for each hybridisation need to be calculated. To do this a 
modal area of a minimum of 50 Mb was taken and compared to the 
area showing the smallest gain of probable significance within the 
same hybridisation. The baseline area was defined as the longest 
contiguous region in which 95% of the clones fell within the 99% 
confidence intervals calculated from the linear ratios of the autosomal 
clones in the normal versus normal hybridisations produced by 
Douglas et al (2004). A Student’s t test comparing the log2 ratios for 
clone in the two areas could then be performed and if the presumed 
area of change was shown to be significantly different this difference 
could be taken as the threshold limit of change for that hybridisation 
and all larger changes could be taken to be significant. The 
significance level for the difference between the tumour and pooled 
female normal log 2 ratios was set at p<0.0001. Copy number 
changes for sex chromosomes were not assessed. In practice a 
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minimum of 3 clones was accepted as showing a meaningful area of 
gain or loss and gains and losses composed of one or two clones 
were not considered of significance unless they were supported by 
similar changes in other experiments. Areas of gain or loss that were 
obviously markedly larger that the threshold level set to represent 
likely single copy change were noted but no arbitrary threshold level 
for such change was set. A BAC clone having been defined as 
showing no significant change, gain or loss it was assigned a value 
of 0, 1 or -1. Using this scoring it was then possible to compare gains 
and losses at each BAC location across all the cancers. Results were 
produced to compare whole chromosomal gain and loss, and 
chromosomal arm changes for the survival groups.  
2.7 In Situ Hybridisation  
This procedure assesses the levels of RNA relating to a specific 
gene in tissue and so investigates gene expression. A labelled probe 
is hybridised against RNA in tissue sections mounted on glass slides. 
A single stranded RNA probe (riboprobe) complementary to the 
target RNA is produced and labelled with a radioisotope. The 
hybridised probe is visualized using autoradiographic procedures. 
The localization of the silver grains is often visualized using dark field 
microscopy. 
ISH was carried out according to an isotope method previously 
described by Jeffrey  ( Jeffrey et al 2005).  
Riboprobes are single-stranded RNA molecules synthesized by in 
vitro transcription 
using a DNA-directed RNA polymerase (SP6, T3, or T7), sufficient 
nucleoside triphosphates (including UTP), and a suitable DNA 
template. Templates are lengths of double-stranded DNA bearing the 
sequence for RNA polymerase binding and initiation, followed by a 
sequence that is specific to the target RNA. A riboprobe capable of 
binding to an mRNA must be a strand complementary to the target 
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mRNA, i.e., an RNA version of the non-coding strand. Usually, 
templates are made from plasmid DNA that has been linearized with 
a restriction endonuclease. Large amounts of good-quality template 
can be produced from a cloned cDNA fragment in a plasmid vector.  
Probes were prepared according to the following method. To a 
microfuge tube,  50 µg plasmid DNA (approx 1 mg/mL solution in TE 
or water), 35 µL of 10X restriction endonuclease buffer appropriate to 
the chosen restriction enzyme, and nuclease-free water to 340 µL 
were added. These were mixed, and then 3.5 µL removed as a “pre-
digest” sample to be kept at –20°C for later analysis.  10 µL of 
chosen restriction enzyme (10 U/µL) was then added, mixed, and 
incubated at the temperature specified by the enzyme supplier for 3–
4 h. Ingredients were mixed, and then 3.5 µL removed as a “post-
digest” sample to be kept at –20°C for later analysis. 350 µL of 
phenol/chloroform were added and the mixture shaken gently to 
emulsify for 2 min, then centrifuged at 13,000g for 5 min in a bench-
top microcentrifuge. The upper (aqueous) phase was then 
transferred to a fresh microfuge tube, taking care to avoid the 
interphase. The last two steps were then repeated. 300 µL of 
chloroform/isoamyl alcohol were added, the mixture shaken gently to 
emulsify for 2 min, and then centrifuged at 13000g for 5 minutes. The 
upper (aqueous) phase was transferred to a fresh microfuge tube, 
taking care to avoid the interphase. 100 µL of 7.5 M ammonium 
acetate were added and then 750 µL of ethanol added. The mixture 
was allowed to stand for approximately 30 minutes at room 
temperature. The DNA was pelleted at 13,000g for 15 minutes. The 
supernatant was discarded, and then 1 mL of 70% ethanol added. 
The DNA was pelleted at 13,000g for 15 minutes. All of the 
supernatant was discarded by careful pipeting, and the pellet allowed 
to air-dry for about 15 minutes. 
25 µL of 10 mM Tris-HCl and 0.1 mM EDTA (pH 7.6) were added to 
dissolve the 
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template DNA (37°C, 10 min).1 µL was removed as a “final template 
sample.” The stock template solution can be stored at –20°C for 
several years. The efficiency of plasmid cleavage production was 
assessed by conventional 1% agarose ethidium bromide gel 
electrophoresis of the three samples taken. The concentration of the 
final template solution was measured spectrophotometrically, or 
estimated by comparing the fluorescence of its band with those in the 
pre- and post digestion samples. If necessary, the concentration of 
the final template solution may be adjusted to approximately 1 
mg/mL. 
 
To label the probes, the following were added in order to a microfuge 
tube at room temperature: 2.5 µL of 5X transcription buffer, 1.0 µL of 
RNase inhibitor, 0.7 µL of DTT (100 mM), 2.0 µL of AGC mix, 2.4 µL 
of stock template solution/nuclease-free water (to give 1 µg template 
DNA), 3.5 µL of 35S UTP. g. 0.4 µL (6–8 U) of appropriate RNA 
polymerase (Promega). The mixture was incubated at 37–40°C for 
60 minutes following this the template was destroyed by adding 
DNase I (1 U, 1 µL) and incubating at 37°C for 15 min. During this 
time a Chromaspin-30 column was prepared by centrifugation. DTT 
(10 mM, 25 µL) was added as well as carrier Ribosomal RNA (10 
mg/mL, 1.5 µL) to the reaction mixture tube, and mixed well. A 1-µL 
sample was removed and diluted with 50 µL water, and 3 mL 
scintillant added to estimate the initial 35S present. The bulk of the 
reaction mixture was added to the top of the gel in a Chromaspin-30 
column and centrifuged at 700g for 3 minutes at 15°C, the eluate was 
collected in a new tube containing DTT (100 mM, 4 µL) and RNase 
inhibitor (2 µL). This was mixed well and 1 µL removed for dilution 
with 50 µL water and 3 mL scintillant to estimate the total 35S 
incorporated. Riboprobe quality was assessed by standard 6% 
polyacrylamide denaturing gel electrophoresis (cat. no. EC 
6865580X; Invitrogen, UK) of duplicate aliquots of 106 cpm 
riboprobes (and standard riboprobes) for 55 minutes, dry gel, and 
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exposed to X-ray film for 15 minutes. Meanwhile, riboprobes were 
stored at –20°C until use within a few days. Columns and vials were 
discarded as appropriate for 35S waste. 
Wearing gloves, 4 µm sections were cut, using a microtome with 
disposable blades. The sections were floated using a clean brush or 
forceps onto DEPC-treated water (fresh daily), degassed before use 
if necessary. Sections were collected onto treated microscope slides. 
Sections were dried overnight in 40°C oven in racks or card slide 
trays protected from dust and then dewaxed in fresh xylene for 8 
minutes (two changes) and rehydrated by sequential immersion in 
the rehydrating alcohols plus DEPC for 5 minutes each and then 
rinsed in PBS+. The tissue was permeablised with proteinase K at 
37°C for 10 minutes and rinsed in glycine/2X PBS for 5 minutes to 
block the proteinase then rinsed in PBS+ for 5 minutes and postfixed 
in 4% PFA in PBS for 10 minutes and rinsed in PBS+ a further three 
times, for 5 minutes each rinse. In a fume hood, slides were 
immersed in 500 mL of acetylation buffer for 10 minutes and then 
washed in PBS+, three times, for 5 minutes each wash then 
dehydrated by sequential immersion in the dehydrating alcohols plus 
DEPC for 5 minutes each and air-dried. The specimens were now 
ready for hybridization. For hybridisation riboprobe/water were added 
to the hybridization buffer in a microfuge tube and heated at 80°C for 
1 minute to “denature” the probe then centrifuged briefly to reduce 
aerosols, and then chilled on ice. 20 µL were pipetted onto each 
section (the mix was viscous, so volumes were approximate). An 
RNase-free glass cover slip was gently lowered onto each slide until 
it made contact with the hybridization buffer, and then the buffer 
allowed to spread under the weight of the cover slip. Working in a 
fume hood, the slides were placed horizontally in, for example, 
plastic slide-mailing boxes or Sakura slide racks, and placed in lunch 
boxes humidified with blotting paper saturated with 1X salts and 50% 
formamide. The lunch boxes were sealed with PVC tape and 
incubated overnight at 55°C. For washing all solutions were 
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prewarmed before use. The first wash buffers were placed in water 
baths ready for use the following day: per 25–50 slides, 5 L of TNE 
buffer at 37°C, and 2 L of formamide wash buffer at 55°C. In a fume 
hood, the lunch box containing the slides was opened. The slides 
were removed, and each cover slip removed by soaking in buffer if 
necessary, and placed in a slide rack immersed in 500 mL of 
formamide wash buffer at 55°C on a rocking table, and four changes 
made over a total of 3–4 hours. All traces of the formamide wash 
buffer were removed using nine changes of 500 mL of TNE buffer at 
37°C, shaking over approx 45 minutes. During the TNE washes, 1 
mL of stock RNase A was thawed, and then added to 500 mL of 
TNE. The slides with the RNase A solution were incubated at 37°C 
for 1 hour in a plastic lunch box. Specific containers were kept for this 
step. RNase-contaminated gloves were disposed of. Slides were 
washed in 2X SSC for 30 minutes at 65°C with agitation, twice. 
Slides were then washed in 0.5X SSC for 30 minutes at 65°C with 
agitation. Slides were then passed through graded ethanols (30, 50, 
70, 90, and 100% ethanol), all containing 0.3 M ammonium acetate 
and air-dried and covered to avoid dust. The specimens were now 
ready for autoradiography. In a darkroom, using a 902 filter and a 15-
W bulb, a water bath was heated to 42°C. A metal plate was cooled 
on ice. 25 mL of water was added to a cut-down, 100-mL measuring 
cylinder or beaker in the 45°C bath. Ilford K5 emulsion was added 
until the volume was 40 mL and left for at least 10 minutes to allow 
the emulsion to melt. A test slide was dipped in the solution and the 
back wiped on a paper towel, and then placed on the cooled plate to 
chill the emulsion layer. The slide was held up to a safelight; there 
should be no bubbles (if so, the emulsion was allowed to rest for 
another 5 minutes) and the layer of emulsion should be smooth and 
even with no streakiness (if not, it was mixed again and retested). 
The slides were dipped one at a time into the warm emulsion until the 
tissue section was immersed. In one smooth movement, the slide 
was lifted clear of the emulsion and the end rested on the dipping 
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vessel for approximately 10 seconds to recover the excess. The end 
was wiped and the back of the slide wiped with a paper towel before 
placing it on the cooled plate. The slides were allowed to dry for 
about 2.5 hours, in total darkness if possible, until the surface of the 
emulsion was hard when scratched with a fingernail. The dry slides 
were placed in a wooden (or plastic but not metal) slide 
rack/holder/box and sealed into a light-proof, black plastic bag and 
stored in a 4°C fridge to expose the emulsion. Sets of exposed slides 
were developed in safelight conditions by immersion in 
preprepared Kodak D-19 developer at approx 18°C for 4 minutes, 
agitating each 
minute (using glass or plastic slide carriers). The slides were then 
immersed in 400 mL of stop solution for 30 seconds then immersed 
in tap water for 30 seconds then immersed in 400 mL of sodium 
thiosulfate fixer, with two changes of 4 minutes each. The slides 
could then be exposed to light. Counterstaining of tissues was 
performed by immersing the racked slides in diluted Giemsa’s stain 
for 3–4 minutes. The excess stain was washed off with tap water for 
30 seconds and the slides air-dried and then mounted in DPX under 
glass cover slips.  When the DPX had set, the back of the slides was 
cleaned with a hard-backed blade, then front and back with 70% 
ethanol and paper tissue to remove all traces of emulsion and 
grease. If possible, it was arranged to view the sections using a 
microscope that allowed rapid switching between conventional 
illumination and reflected light. Under conventional illumination with 
100× overall magnification and moderate exposure times, only the 
most intense clusters of black-silver grains could be seen, unless 
much higher magnification is used and the field of view was limited to 
perhaps 100 or 200 cells. In contrast, looking at the same slide in 
reflected light, much lower densities of silver grains were seen easily. 
More importantly, the quality of background obtained can be 
assessed in moments. Sections that in conventional illumination 
appear to have no labelling, may, in fact, reveal significant patterns of 
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mRNA expression in reflected light. With Giemsa’s counterstain, the 
nuclei of cells without nearby grains appear greenish-yellow or 
golden in reflected light, and the threshold for deciding whether a cell 
or cell type is labelled can be chosen while looking at thousands of 
cells and associated extracellular matrices.  Switching between 
conventional illumination and reflected-light, dark-field conditions was 
an extremely useful way to assess whether there were any significant 
patterns of silver grains on the section, or if significant expression 
was occurring in specific regions.  
2.8 Tissue array 
A tissue array is a collection of tissue cores typically 1-3mm in size 
set in paraffin in a grid pattern according to the normal dimensions of 
a pathology slide. A typical array might include 100 such cores. The 
array so constructed allows staining experiments to be performed on 
multiple tissue samples at the same time, a key to the grid allowing 
the identification of the different tissue samples. 
The array used in this work was constructed in the Nuffield pathology 
laboratory in Oxford. It was comprised of colorectal cancer tissue 
cores from patients with clinical follow up measurable in years. 
Sections were taken from  the tissue array block as one would 
normally section paraffin embedded tissue with a microtome. The 
cancers comprising the tissue array formed a completely different 
group to those cancers used in the aCGH work. 
 
2.9 Statistical statement 
Simple proportions were compared using Fisher’s Exact test or the 
Chi-squared test as appropriate. Non-parametric continuous data 
was compared using the Mann-Whitney U test. A power calculation 
as to the number of specimens required for aCGH analysis was 
made on the basis of previous results for 18q LOH. 70% of bad 
76 
 
outcome cancers could be expected to show such LOH and 35% of 
good outcome cancers (Houlston et al 1997). For a one sided test 
with a threshold p value of 0.05 and a power to detect difference of 
>95%, a sample size of at least 45 cancers was required.  
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Chapter 3. 
Sample Collection and Basic 
Clinicopathological Data Analysis  
 
3.1 Introduction  
 
The initial aim was to collect Dukes B colorectal cancer tissue, 
extract DNA from it, gather related clinicopathological and follow up 
data and to relate the clinicopathological data to the follow-up data.  
Dukes B cases with documented 5 year survival or documented 
death within 5 years of surgery were selected. Patients who had died 
directly post-operatively, cases of known inherited cancer (stated in 
the notes as FAP or HNPCC) and cases of cancer related to 
inflammatory bowel disease were excluded. 
 
3.2 Statistical considerations 
 
A power calculation as to the number of specimens required for 
aCGH analysis was made on the basis of previous results for 18q 
LOH. 70% of bad outcome cancers could be expected to show such 
LOH and 35% of good outcome cancers (Houlston et al 1997). For a 
one sided test with a threshold p value of 0.05 and a power to detect 
difference of >95%, a sample size of at least 45 cancers was 
required.  
 
 
3.3 DNA samples  
 
Cancer DNA came from tissue collected at three centres: John 
Radcliffe Hospital, Oxford, Leeds General Infirmary and St Mark’s 
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Hospital Harrow. Post-exclusions, 79 Dukes B cases remained, with 
7 cases excluded (2 post operative deaths, 3 cases of inflammatory 
bowel disease related cancer and 2 cases of FAP related cancer). 
Tissue from Oxford consisted of 45 Dukes B cancer samples with 
paired normal mucosal tissue (these were drawn from a collection of 
142 cancers and 34 adenomas with paired normal tissue, previously 
collected in Oxford, which had been archived by me and from which 
(for the whole set) I had extracted DNA). 26 DNA samples from 
Dukes B cancers with paired normal mucosal DNA were received 
from Leeds and 9 samples of Dukes B tumour were received from St 
Mark’s Hospital. 
All tissue had been snap frozen in liquid nitrogen on collection and 
stored at -70 C. Tissue usage was covered by appropriate ethics 
committee approval which I  obtained myself (C03.137/C03.077). 
The Oxford tissue was processed by me. Leeds sample DNA was 
extracted by local researchers. The St Mark’s tissue was collected 
locally and processed by researchers in the CRUK Molecular and 
Population Genetics Laboratory who supplied data which were used 
by me. To our knowledge no patient included in this study received 
adjuvant therapy. 
 
3.4 Processing of tissue  
 
The fresh-frozen Oxford samples were cut into pieces, one piece 
being placed in formalin and blocked in paraffin wax and the second 
piece being frozen and used for DNA extraction by standard 
methods. Samples of extracted DNA were archived for future use 
along with the residual tissue. DNA was extracted (Methods 2.1) and 
DNA concentration and quality assessed (Methods 2.2). Pathological 
examination of all Oxford tissue was undertaken by Professor M. 
Ilyas to confirm the nature of the tissue.  
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Tissue from Leeds was subjected to micro-dissection and DNA 
extracted by standard methods. 
Tissue from St Mark’s tumours was treated in the same way as that 
from Oxford. This processing was performed in the CRUK laboratory. 
 
3.5 Clinicopathological data 
 
Follow up data and clinicopathological data was obtained from 
patient records in the case of the Oxford samples and the St Mark’s 
samples according to ethics committee approval. Follow up data and 
clinicopathological data for the Leeds samples was kindly supplied by 
Professor Quirke’s team. 
 
3.6 Clinicopathological data results 
 
For the 79 Dukes B patients with adequate follow up, 43 (54.4%) had 
at least 5 year survival and 36 (45.6%) less than 5 years survival 
from the time of operation. For the Leeds samples this was the only 
information available (i.e no exact time to death just 5 year survival 
+/-).  
Comparison of clinicopathological data for the two survival groups 
can be seen in Table 2.1. There was a significant difference between 
the two groups for T4 stage (> 5 year 16.3% versus < 5 year 36.1% 
p= 0.043). The > 5 year survival group contained significantly more 
cancers from Leeds (44.2% versus 16.7% p=0.014) and significantly 
less cancers from Oxford (39.5% versus 77.8% p=0.0007). 
 
                                               
 
 
 
 
 
80 
 
 
 
TABLE 2.1 Clinicopathological variables in relation to 5 year 
survival for 79 Dukes B cancers. 
 
Survival                  >5 year (%)      <5 year (%)                P 
Sample source 
Oxford 17(39.5)  28(77.8)         0.0007 
Leeds  19(44.2)  6(16.7)            0.014  
St Marks 7(16.3)  2(5.6)   0.17  
Gender          19(44)                   16(44)    1.0 
(female)                         
Mean Age      66+/-5.2                   70.6+/-6.1  0.47  
(years)                              
Tumour site  
Right        13(30.2)                  10(27.8)  1.0                                            
Left          16(37.2)                      9(25)  0.33                                                
Rectal      14(32.5)                  17(47.2)  0.25                         
Grade (differentiation)           
Well          7(16.2)                   3(8.3)   0.33                            
Mod          31(72.1)                    32(88.9)  0.09                        
Poor          5(11.6)                     1(2.8)   0.21                             
T stage         
T4             7(16.3)                   13(36.1)     0.043* 
LVI                6(13.9)                        3(8.3)          0.49                           
 
LVI=Lymphovascular invasion 
 
 
 
3.7 Discussion 
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Although the power calculation suggested that 45 samples would be 
adequate for this project, we thought that analysing as many samples 
as possible was sensible. This was because the LOH test on which 
the power calculation was based was a very different technique to  
aCGH and while providing a guideline to numbers was unlikely to 
have produced a reliable figure on which to base project numbers. In 
practice the limit of numbers in this work was placed by scarcity of 
arrays for the aCGH and scarcity of DNA from colorectal cancers 
derived from patients for whom long term follow up data was 
available. In order to maximise the number of samples in the study 
we collected samples from 3 centres (Oxford, Leeds and St Marks).  
 
There were differences between the centres in how the samples had 
been processed and the amount of follow up data available. 
However, it was felt that these differences were more than made up 
for by the increase in samples involved in the work. 
 
The method of processing the Oxford samples introduced uncertainty 
as to the percentage of cancer in the analysed sample. While tumour 
content was at least 60% in all analysed samples according to the 
tissue on which histological analysis was performed, this assumes a 
similar proportion of tumour in the sample used for DNA extraction 
which may not have been the case.  
 
Ideally cause of death, time of death and disease progression would 
have been available for all cases, allowing comparison of cases 
according to cancer specific survival, disease progression and local 
recurrence. However, for the Leeds samples only information relating 
to overall 5 year survival was available. Strenuous efforts were made 
to obtain more data but this proved impossible. 
 
The 5 year survival of 54% for Dukes B cancer was poor but the 
cancers examined here do not represent a cohort drawn from a 
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consecutive experience in a single centre, simply those Dukes B 
cancers available for analysis with adequate additional data. It is a 
bonus that the cancers were split more evenly than would be 
expected as it gives a greater number of cases in the poor survival 
group. It is likely in the case of the Oxford samples that previous 
experiments had exhausted collected tissue in an uneven way 
leading, perhaps, to a disproportionate use of tissue from good 
outcome cases. 
 
The Leeds cancer DNA was produced from microdissected tissue 
samples and might be expected to give better results for some 
experiments than the other samples because of less normal tissue 
contamination. There was a significant difference between the 
survival groups for the percentage of Leeds cancers (>5 years 44.2% 
versus <5 years 16.7% p=0.014). Previous experiments from our 
laboratory had, however, shown very comparable results between 
DNA samples with 60% and 100% cancer tissue. 
 
In terms of the poor survival group having a higher number of T4 
cancers, T stage is one of the most powerful prognostic markers 
(Introduction 1.4.1) and this difference is expected. However, the 
difference between the two groups in terms of T4 proportion 
represents a problem in terms of comparing molecular markers 
between the groups since outcome difference may be dictated more 
by the stage of the cancer than the biology of the cancer.  
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Chapter 4 
Comparison of MSI, Ploidy, and 
APC LOH for the Dukes B Cancer 
Survival Groups. 
 
4.1 Introduction  
 
The Dukes B cancers were assessed for MSI status, ploidy and APC 
LOH. It was of interest to test the prognostic significance of MSI and 
ploidy. Microsatellite stable and aneuploid cancers have been shown 
in previous work to have worse outcome (Introduction 1.4.2). 
It was also important to subdivide the survival groups by 
chromosomal instability status before comparison of the aCGH 
results was made since these groups are known to have marked 
aCGH difference (Douglas et al 2004, Jones et al 2005). 
 
 
4.2 MSI and LOH analysis 
For MSI and LOH analyses, the tumour DNA was PCR-amplified 
alongside the normal mucosal DNA from the patient using 
microsatellite markers (BAT 26, D5S356) -Methods 2.3 and 2.4. 
Description of primers and reaction conditions can be found in 
Appendix 1.  
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4.4 MSI results 
 
There was no difference between the survival groups for MSI+ (> 5 
year survival 18.6% versus < 5 year survival 16.7% p=1.0) (Appendix 
2).  
 
 
 
 
4.5 LOH results (Appendix 2) 
There was no significant difference between the survival groups 
shown by D5S346 (APC) LOH (for informative cases, >5 years 
survival group 55.6% versus < 5 years survival group 32% p=0.17). 
 
4.6 FACS analysis  
 
Samples from Oxford and St Marks underwent flow cytometry 
analysis for ploidy. The work on the Oxford samples was performed 
by me (Methods 2.5) and the work on the St Marks samples 
performed previously at CRUK. 
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 Figure 4.1  Example of D5S346 MSI+ (Normal mucosa above 
and cancer tissue below)  
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Figure 4.2 Example of D5S346 LOH. Normal sample on left and 
tumour on right. Ratio of peaks 80713/65407 x 13395/83657 = 0.2 
( <0.5 and thus demonstrating LOH) 
 
                                  
  
 
 
 
 
Figure 4.3 Bat 26 MSI+ (Normal tissue above and cancer tissue 
below). Notice additional peaks on left. 
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4.7 FACS results (Appendix 3) 
 
50 results were available with 3 failures of the tested samples. There 
was no significant difference in aneuploidy between the survival 
groups (>5 year survival 43.5% versus < 5 year survival 55.6% 
p=0.57), although there were a greater number of aneuploid cancers 
in the poor survival group. 
 
Figure 4.4. Examples of FACS for aneuploid cancer (left) and 
diploid cancer (right). 
             
        
                    ↑                                                                                    ↑ 
                   2N                                                                                    2N 
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4.8 Discussion 
 
MSI and LOH 
Although no significant difference in rates of MSI was seen between 
the two survival groups MSI has been shown in a number of studies 
to be associated with improved survival (Allen et al 2005). Studies 
have confirmed a consistent and independent association between 
MSI-high phenotype and improved survival in stage II and III CRC 
patients. A systematic analysis of 215 sporadic colorectal cancer 
patients showed that those with microsatellite instability had a 
survival advantage over patients without it, independent of other 
prognostic factors. Microsatellite instability was found in 16.4% of 
colorectal cancers. The hazard ratio of patients with tumours showing 
microsatellite instability to those without was estimated to be 0.39 
(95% CI 0.19 to 0.82) (Bubb et al 1996). More recently a systemic 
review (Popat et al 2005) showed a hazard ratio for overall survival 
associated with MSI of 0.65 (95% CI 0.59-0.71). 
 
5q harbours the APC gene thus LOH at this locus is more likely to be 
related to tumour initiation than cancer progression and hence 
prognosis. Unsurprisingly then no studies have demonstrated a link 
between LOH at this locus and prognosis (Houlston et al 1997).  
 
 
Ploidy 
 
Although the difference was not statistically significant more 
aneuploidy was seen in the poor outcome group.  
A recent meta-analysis (Araujo et al 2007) has studied the 
relationship between aneuploidy and prognosis. The main outcome 
measure was the five-year overall mortality rate after surgical 
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resection. For patients with Stage II colon cancer there was an 
absolute reduction of 14.3 percent in five-year overall mortality 
favouring diploid tumours. Additionally Walther et al (2008) produced 
a meta-analysis showing aneuploidy to be associated with poor 
prognosis (hazard  ratio 1.45 (95% CI 1.35-1.55)). 
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Chapter 5.  
Comparison of Array Comparative 
Genomic Hybridisation Results for 
the Dukes B Cancer Survival 
Groups 
 
5.1 Introduction 
 
As outlined in the introductory Chapter, aCGH provides a method of 
assessing genomic gains and losses in DNA samples. To examine 
differences in Dukes B cancers with good and bad survival, we 
examined 79 cancers using aCGH. The samples used were those 
already detailed in the previous chapters. The cancers were 
analysed using 2 different arrays, based on the same platform and 
with very similar content, one provided by the Sanger Laboratory in 
Cambridge and the other by the Wellcome group based in Oxford. 53 
samples were examined using the Sanger array and 26 using the 
Wellcome array. These arrays used the same BAC clones. The 
values for all clones for the 79 samples compose too large a data set 
to be given here, but can be provided in disc form on request.  
 
5.2 aCGH Results  
 
To compare results, I calculated whole chromosomal changes, part 
chromosomal  changes and changes per individual BAC. These 
results are provided for the whole group of 79 cancers, for the > 5 
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year/<5 year survival groups and for the survival/MSI subgroups. 
Small changes (<10Mb) and areas of very marked copy number gain 
are also given. Appendix 7 shows all aCGH results. In Appendix 7 
large gain signifies gain of a length of chromosome >10Mb. Small 
gain signifies gain <10Mb. Supernormal gain represented a log2 ratio 
twice as large as would qualify as a simple gain. 
 
 
5.3 Results for all Dukes B cancers  
 
Considering all chromosomal scale changes (gains and losses of any 
part of the chromosome > 10Mb) 20.3% of all chromosomes showed 
change, with 9.7% showing gains and 10.7% losses. 
The most commonly gained whole chromosomes were 13 (64.5%), 
20 (45.6%), 7 (38%), 21 (24%), 10 (21.6%). The most commonly lost 
whole chromosomes were 22 (60.7%), 18 (51.9%), 14 (32.9%), 21 
(27.8%), 1 (26.6%), 15 (26.6%), 19 (25.3%), 9 (22.8%).  
Considering any gains or losses of p arm sections > 10Mb most 
common gains were for chromosomes 20 (49.4%), 7 (43%), 6 
(25.3%), 10 (22.8%), 19 (21.5%) and 11 (20.2%). Most common 
losses were for chromosomes1 (69.6%), 18 (58.2%), 17 (62%), 8 
(46.8%), 19 (26.6%), 20 (26.6%), 9 (22.8%). 
Considering all q arm section changes >10 Mb most common gains 
were seen for chromosomes 20 (69.6%), 13 (59.5%),  8 (51.9%),  7 
(40%),  21 (24%),  10 (22.8%),  11 (22.8%). Commonest losses were 
for chromosomes 22 (62%),  18 (54.4%),  15 (31.6%),  19 (30.4%),  
14 (29.1%),  1 (27.8%),  21 (27.8%), 9 (25.3%) and 4 (20.25%). 
5.5 Comparison of aCGH results for 5 year survival groups 
(Appendix 8) 
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For the >5 year survival group 20.4% of chromosomes showed 
chromosomal scale changes with 9.8% gains and 10.6% losses. For 
the <5 year survival group 20.2% (p=0.84) of chromosomes showed 
chromosomal scale changes with 9.4% (p=0.6) showing gains and 
10.7% (p=0.83) losses. 
Whole chromosome 
 Largest differences in terms of gain were for chromosomes 10, 16, 
19 and 22, However none of these differences was statistically 
significant. Comparing whole chromosomal losses the largest 
difference were seen for chromosomes 4,6,14,19,21,22. Here the 
only statistically significant difference was for chromosome 6 (7/43 
versus 0/36 p<0.014). 
p arm section >10Mb 
Largest differences were seen for chromosomes 5, 6, 12 and 16 with 
differences for chromosomes 5 and 16 approaching significance 
(11/43 versus 3/36 p=0.07 and 9/43 vs 2/36 p=0.06). Comparing 
losses largest differences were seen for chromosomes 4,5,6,10 and 
20 with difference for chromosomes 4 and 5 reaching statistical 
significance (3/43 versus 9/36 p=0.03 and 0/43 versus 6/36  
p=0.007). 
q arm section >10Mb 
Comparing gains between survival groups most difference was seen 
for chromosomes  6, 9 and 16. For losses most difference was seen 
for chromosomes 5, 19 and 21. None of these differences reached 
significance. 
5.5 Comparison of aCGH results for MSI- survival groups 
(Appendix 8) 
Considering the MSI- group as a whole 22.1% of chromosomes 
showed change, 10.6% gain and 11.5% loss. For the >5 year 
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survival group 22.4% of chromosomes showed change, 10.8% gain 
and 11.6% loss. For the <5 year survival group 21.7% (p= 0.52) of 
chromosomes showed change, 10.3% (p= 0.61) gain and 11.3% (p= 
0.72) loss. 
Whole chromosome  
Most difference was seen for chromosomes10 and 16. Differences 
for 16 reached significance (>5 year survival 6/35 versus <5 year 
survival 0/30 p=0.027). Comparing whole chromosome loss most 
difference was seen for chromosomes 4, 6 and 10 with chromosome 
6 difference reaching significance (6/35 versus  0/30 p=0.027). 
 p arm section >10 Mb 
Largest difference was seen for chromosomes 5, 6, 10 and 16 with 
chromosome 16 differences reaching statistical significance (9/35 
versus 1/30 p<0.016). Comparing losses most difference was seen 
for chromosomes 1,3,4,5,6 and 10 with differences for chromosomes 
4 and 5 reaching statistical significance (3/35 versus 9/30 p<0.05 and 
0/35 versus 5/30 p<0.017). 
q arm section >10Mb 
 Largest difference was seen for chromosomes 9,13 and 16. 
Comparing losses chromosome 15 showed most difference. None of 
these differences was statistically significant. 
5.6 Comparison of aCGH results for MSI+ survival groups 
(Appendix 8) 
Considering the MSI+ group as whole 12.1% of chromosomes 
showed changes, 5.2% gain and 6.8% loss. For the >5 year survival 
group 11.5% of chromosomes showed change, 5.4% gain and 6.1% 
loss. For the <5 year survival group 12.6% (p= 0.57) of 
chromosomes showed change, 4.9% (p= 0.78) gain and 7.9% (p= 
0.28) loss. 
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Whole chromosome  
Comparing whole chromosome gain for microsatellite unstable 
cancers most difference was seen for chromosome 20 with no 
changes reaching significance. Comparing whole chromosome loss 
most difference was seen for chromosomes 20, 21 and 22 with no 
differences reaching significance. 
p arm section >10 Mb 
For microsatellite unstable cancers the largest difference for gains 
was for chromosomes 5,6 and 18. For losses largest difference was 
seen for chromosomes 1,6,8,18,19 and 20. None of these 
differences reached statistical significance. 
q arm section >10Mb 
Comparing gains in microsatellite unstable cancers most difference 
was seen for chromosomes 6,9 and 17. Comparing losses most 
difference was seen for chromosomes13,16,18,19,20 and 21. None 
of these differences reached statistical significance.  
5.7 Results at the level of individual BAC clones  
Appendices 9 and 10 show the most commonly gained and lost BAC 
clones. For all cancers the percentage of clones showing gain was 
11.4%. Those cancers from patients with 5 year survival showed an 
average of 12.7% gain. Those without 5 years survival showed 9.9% 
of clones showing gain. In patients with 5 years survival and 
microsatellite stability 14.7% of clones showed gains. Those patients 
with microsatellite stable cancers without 5 year survival showed 
10.8% of clones showing gain. Patients with microsatellite unstable 
cancers with 5 year survival showed 3.8% clonal gains as against 5% 
in those with microsatellite unstable cancers without 5 year survival. 
For all cancers the percentage of clones showing losses was 9.8%. 
Those cancers associated with 5 year patient survival showed 9% 
95 
 
clonal losses compared with 10.7% for cancers associated with less 
than 5 year survival. For microsatellite stable cancers associated with 
5 year patient survival 11.4% of clones showed losses compared 
with 11.4% for those not associated with 5 year survival. For patients 
with microsatellite unstable cancers associated with 5 year survival 
5.6% of clones showed losses compared with 7.3% in those not 
associated with 5 year survival. 
Looking at the largest gains for microsatellite stable cancers 
associated with >5 year survival these were 13, 23-27.9 Mb (77.1%), 
chr 20 49.3-63.4 Mb (74.4%) and chromosome 8 41.8-145.7 Mb 
(60%). For microsatellite stable cancers associated with < 5 year 
survival the highest percentage gains were for chromosomes 20 
34.9-63.4 Mb (79.3%), 13 0-113.8 Mb (65.5%) and  8 90.6-128.4 and 
138.9-145 Mb (62%).  
For microsatellite unstable cancers associated with >5 year patient 
survival largest gains were seen for chromosomes 7 0-14.7 Mb and 
98.5-101 Mb (50%) and  8 144.2-145 Mb (50%). For those 
microsatellite unstable cancers not associated with 5 year patient 
survival the greatest gains were seen for chromosomes 8 40.9-145.7 
Mb (66.7%), 6 56.7%-75.9 Mb (50%), 20 33.8-63.4 Mb (50%). 
The greatest losses for microsatellite stable cancers associated with 
> 5 year patient survival were chromosomes1 8.9-24.2 Mb (77.1%), 8 
0-3.7 Mb (48.6%) and 17 0-20.1 Mb (68.6%). For those not 
associated with 5 year patient survival largest losses were seen at 
chromosomes1 0-23.6 Mb (70%), 8 0-30.7% (50%), 14 0-105.1 Mb 
(40%) and 17 0-20.1 Mb (70%).  
For microsatellite unstable cancers associated with >5 year patient 
survival chromosome 20 showed an area (0-63.4 Mb) with 50% loss. 
For microsatellite cancers not associated with 5 year patient survival 
the greatest losses were chromosomes1 0-45 (83.3%), 8 0-34.1 Mb 
(50%) and 9 119.9-134 Mb (66.6%). 
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5.8 Small Areas of gain and loss 
These areas of gain and loss (Appendix 11 and 12) of <10Mb were 
recorded for the outcome groups stratified by microsatellite status. It 
may be seen that such losses and gains are not common and are 
seldom repeated more than a few times in our sample. As such 
comparison of the outcome groups does not show obvious difference 
that is useful in a prognostic sense. Total numbers of such changes 
were highest in the poor outcome microsatellite stable group but not 
significantly so. 
 5.9 Areas of greater than single copy number change (Appendix 
13) 
These are areas of greater than single copy number change as 
defined above. Again it may be seen that for the most part such 
changes are uncommon and rarely repeated. However for 
chromosome 13 gain significant difference was found between the 
poor outcome group (8/36) and the good outcome group (0/43) 
(p=0.001). 
 
 
Figure 5.1- 5.5.  Examples of array CGH derived data shown as 
plots of log2 ratio of signal intensity (cancer compared with 
pooled normal DNA) against chromosomal position in Mb. 
Results are shown by chromosome. Examples are shown of 
CIN+ type change, MSI+ type change and specific small length 
gains and losses.  
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    Figure 5.1 CGH result- MSI+ cancer showing minimal change. However, sub arm length change is 
seen for chr 6 and gain is seen for the whole of chromosome 8   
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 Figure 5.2. CGH result showing gain of a small section of chr 13 
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    Figure 5.3 Second CGH result showing gain of same area of chr 13 
 
C
h
ro
m
o
s
o
m
e
 1
-2
-1
.5-1
-0
.50
0
.51
1
.52
0
5
0
1
0
0
1
5
0
2
0
0
2
5
0
3
0
0
M
il
li
o
n
s
d
is
ta
n
c
e
 i
n
 b
p
log2(ratio)
C
h
ro
m
o
s
o
m
e
 1
0
-2
-1
.5-1
-0
.50
0
.51
1
.52
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
M
il
li
o
n
s
d
is
ta
n
c
e
 i
n
 b
p
log2(ratio)
C
h
ro
m
o
s
o
m
e
 1
1
-2
-1
.5-1
-0
.50
0
.51
1
.52
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
M
il
li
o
n
s
d
is
ta
n
c
e
 i
n
 b
p
log2(ratio)
 
C
h
ro
m
o
s
o
m
e
 1
2
-2
-1
.5-1
-0
.50
0
.51
1
.52
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
M
il
li
o
n
s
d
is
ta
n
c
e
 i
n
 b
p
log2(ratio)
C
h
ro
m
o
s
o
m
e
 1
3
-2
-1
.5-1
-0
.50
0
.51
1
.52
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
M
il
li
o
n
s
d
is
ta
n
c
e
 i
n
 b
p
log2(ratio)
C
h
ro
m
o
s
o
m
e
 1
4
-2
-1
.5-1
-0
.50
0
.51
1
.52
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
M
il
li
o
n
s
d
is
ta
n
c
e
 i
n
 b
p
log2(ratio)
C
h
ro
m
o
s
o
m
e
 1
5
-2
-1
.5-1
-0
.50
0
.51
1
.52
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
M
il
li
o
n
s
d
is
ta
n
c
e
 i
n
 b
p
log2(ratio)
C
h
ro
m
o
s
o
m
e
 1
6
-2
-1
.5-1
-0
.50
0
.51
1
.52
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
9
0
M
il
li
o
n
s
d
is
ta
n
c
e
 i
n
 b
p
log2(ratio)
C
h
ro
m
o
s
o
m
e
 1
7
-2
-1
.5-1
-0
.50
0
.51
1
.52
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
9
0
M
il
li
o
n
s
d
is
ta
n
c
e
 i
n
 b
p
log2(ratio)
C
h
ro
m
o
s
o
m
e
 1
8
-2
-1
.5-1
-0
.50
0
.51
1
.52
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
9
0
M
il
li
o
n
s
d
is
ta
n
c
e
 i
n
 b
p
log2(ratio)
C
h
ro
m
o
s
o
m
e
 1
9
-2
-1
.5-1
-0
.50
0
.51
1
.52
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
M
il
li
o
n
s
d
is
ta
n
c
e
 i
n
 b
p
log2(ratio)
C
h
ro
m
o
s
o
m
e
 2
-2
-1
.5-1
-0
.50
0
.51
1
.52
0
5
0
1
0
0
1
5
0
2
0
0
2
5
0
3
0
0
M
il
li
o
n
s
d
is
ta
n
c
e
 i
n
 b
p
log2(ratio)
C
h
ro
m
o
s
o
m
e
 2
0
-2
-1
.5-1
-0
.50
0
.51
1
.52
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
M
il
li
o
n
s
d
is
ta
n
c
e
 i
n
 b
p
log2(ratio)
C
h
ro
m
o
s
o
m
e
 2
1
-2
-1
.5-1
-0
.50
0
.51
1
.52
0
5
1
0
1
5
2
0
2
5
3
0
3
5
4
0
4
5
5
0
M
il
li
o
n
s
d
is
ta
n
c
e
 i
n
 b
p
log2(ratio)
C
h
ro
m
o
s
o
m
e
 2
2
-2
-1
.5-1
-0
.50
0
.51
1
.52
0
1
0
2
0
3
0
4
0
5
0
6
0
M
il
li
o
n
s
d
is
ta
n
c
e
 i
n
 b
p
log2(ratio)
C
h
ro
m
o
s
o
m
e
 3
-2
-1
.5-1
-0
.50
0
.51
1
.52
0
5
0
1
0
0
1
5
0
2
0
0
2
5
0
M
il
li
o
n
s
d
is
ta
n
c
e
 i
n
 b
p
log2(ratio)
C
h
ro
m
o
s
o
m
e
 4
-2
-1
.5-1
-0
.50
0
.51
1
.52
0
5
0
1
0
0
1
5
0
2
0
0
2
5
0
M
il
li
o
n
s
d
is
ta
n
c
e
 i
n
 b
p
log2(ratio)
C
h
ro
m
o
s
o
m
e
 5
-2
-1
.5-1
-0
.50
0
.51
1
.52
0
5
0
1
0
0
1
5
0
2
0
0
M
il
li
o
n
s
d
is
ta
n
c
e
 i
n
 b
p
log2(ratio)
C
h
ro
m
o
s
o
m
e
 6
-2
-1
.5-1
-0
.50
0
.51
1
.52
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
1
8
0
M
il
li
o
n
s
d
is
ta
n
c
e
 i
n
 b
p
log2(ratio)
C
h
ro
m
o
s
o
m
e
 7
-2
-1
.5-1
-0
.50
0
.51
1
.52
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
1
8
0
M
il
li
o
n
s
d
is
ta
n
c
e
 i
n
 b
p
log2(ratio)
C
h
ro
m
o
s
o
m
e
 8
-2
-1
.5-1
-0
.50
0
.51
1
.52
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
M
il
li
o
n
s
d
is
ta
n
c
e
 i
n
 b
p
log2(ratio)
C
h
ro
m
o
s
o
m
e
 9
-2
-1
.5-1
-0
.50
0
.51
1
.52
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
M
il
li
o
n
s
d
is
ta
n
c
e
 i
n
 b
p
log2(ratio
C
h
ro
m
o
s
o
m
e
 X
-2
-1
.5-1
-0
.50
0
.51
1
.52
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
M
il
li
o
n
s
d
is
ta
n
c
e
 i
n
 b
p
log2(ratio)
C
h
ro
m
o
s
o
m
e
 Y
-2
-1
.5-1
-0
.50
0
.51
1
.52
0
5
1
0
1
5
2
0
2
5
3
0
M
il
li
o
n
s
d
is
ta
n
c
e
 i
n
 b
p
log2(ratio)
100 
 
     
  Figure 5.4 CGH result showing typical CIN+ type changes (gain chr 13, 20q(++), loss chr 18) 
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 Figure 5.5. Second CGH result showing multiple genomic changes (note gain of small region of chr 
2). 
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5.10  aCGH Discussion. 
Array CGH has not been previously used in relation to prognosis for 
Dukes B colorectal cancer alone. We were unable to find marked 
difference between the outcome groups. 
Comparing survival groups, chromosome 6 was more often lost in 
good outcome cancers, chromosome 16 was more often gained in 
good outcome microsatellite stable cancers. 
Considering part p arm changes, cancers associated with good 
patient prognosis showed more gain of 5 and 16 and cancers 
associated with poor patient outcome showed more loss of 4 and 5. 
Considering microsatellite stable cancers, cancers associated with 
good patient outcome showed more gain of 16 and cancers 
associated with bad patient outcome showed more loss of 4 and 5.  
Considering high amplitude areas of gain, whole chromosome 13 
gain was seen significantly more often in cancers associated with 
bad patient outcome.  
Clearly these differences may simply be the result of multiple testing. 
We have performed no formal Bonferroni correction, but if one takes 
a more stringent level for statistical significance (p<0.01) then only 5p 
loss and high amplitude gain of chromosome 13 retain significance. 
5p loss was seen in only one sixth of bad outcome cancers and high 
amplitude gain of chromosome 13 was seen in only 8 of 36 bad 
outcome cancers, and therefore neither can be suggested as a 
useful predictor of outcome. 
On a more positive note several novel areas of gain and loss were 
detected namely gains of chromosome 1 82-86 Mb, 3 66.7-74 Mb, 5 
40.1-49.9 Mb, 6 149.5-156.9 Mb, 7 20-23.5, 13 19.1-27.9, 15 25-34 
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Mb, 16 84.6-89.7 Mb and losses of chromosome 7 62-67 Mb, 9 25.7-
29.1, 12 74.7-82.3 Mb.  
The samples from Leeds were microdissected and results from these 
cancers are likely to be of higher quality than those from Oxford and 
St Mark’s. Without microdissection and using the histopathological 
analysis the estimated percentage content of the cancer within the 
specimen may not accurately reflect the percentage of cancer in the 
sample used to obtain DNA for analysis. In all cases the percentage 
of tumour is likely to be less than for the microdissected samples. 
The Oxford and St Mark’s samples made up 40% of the 
microsatellite stable 5 year survival group (5+M-), 37.5%  of the 
microsatellite unstable 5 year survival group (5+M+), 73.3% of the 
microsatellite stable < 5 year survival group (5-M-), and 100% of the 
microsatellite unstable <5 year survival group (5-M+). It may be seen 
that these samples are unequally spread across the 4 groups thus 
introducing possible bias. The Oxford samples were likely to contain 
a larger amount of normal tissue than other samples and this was 
likely to result in fewer chromosomal changes than undiluted 
samples.  
Considering analysis of the whole group this is in line with previous 
analysis of colorectal cancer with array CGH. Hughes et al (2006) 
performed a meta-analysis of all previous CGH results for CRC. 
Gains of 20, 13q, 8q and 7p and loss of 18, 17p, 8p and 4p were the 
most frequent changes. Pooling identified less frequent, but 
significant changes, including gain of 1q and 3, and losses from 6q, 
9p and 21q.  
 
 Considering publications showing series of CRC analysed with array 
CGH Nakao et al (2004) examined 125 CRC and found an overall an 
average of 17.3% (8.5% gain and 8.8% lost) of the genome altered . 
Common losses involved 8p, 17p, 18p or 18q occurring in 
respectively 37%, 46%, 49% and 60% of cases. Common gains were 
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8q and 20q gained in 42% and 65% of cases. Significant difference 
was seen between MSI +/- CRC with average genomic alteration 
being respectively 5% and 20%. MSI+ showed some copy number 
change most often at 8q. Douglas et al (2004) investigated copy 
number changes in 48 colorectal cancer (CRC) cell lines and 37 
primary CRCs. The samples were divided for analysis according to 
the type of genomic instability that they exhibited; microsatellite 
instability (MSI) or chromosomal instability (CIN). Consistent copy 
number changes were identified, including gain of chromosomes 20, 
13, and 8q and smaller regions of amplification such as chromosome 
17q11.2-q12. Loss of chromosome 18q was a recurrent finding along 
with deletion of discrete regions such as chromosome 4q34-q35. A 
greater number of aberrations were detected in CIN+ than MSI+ 
samples as well as differences in the type and extent of change 
reported. For example, loss of chromosome 8p was a common event 
in CIN+ cell lines and cancers but was often found to be gained in 
MSI+ cancers. In addition, the target of amplification on chromosome 
8q appeared to differ, with 8q24.21 amplified frequently in CIN+ 
samples but 8q24.3 amplification a common finding in MSI+ 
samples. 
In terms of prognosis a small number authors have used array CGH 
to address this (although none had done so at the time of planning 
this research (2003)) Nakao et al (2004) did not find copy number 
changes to be associated with tumour stage, location, age or sex. Al-
Mulla et al (2006) examined copy number change in relation to 
survival for 56 patients with stage I and II cancers. All were examined 
using conventional CGH with 10 cases being further examined with 
array CGH. The cancers were not stratified according to stability type 
but the majority were reported as being CIN+MSI-. Metastatic 
cancers had more complex genomic alterations than non-metastatic 
cancers. Loss of chromosome 4p was an independent prognostic 
marker for poor outcome on multivariate analysis. Loss of both 8p 
and 18q had a statistically significant negative effect on disease free 
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survival. Loss of both 4p and 14q was associated with poorer 
prognosis than loss of either one of these genes singly. Multivariate 
analysis showed loss of 4p and 5q to be independent prognostic 
factors. 
Mehta et al (2005) used aCGH to try and predict cancer recurrence 
following the resection of hepatic metastases. They performed aCGH 
on 50 cancers and compared the results of aCGH data and a 
clinicopathological scoring system with outcome results. In general 
they found on average 30% of the genome to be altered (14% gain 
and 16% loss). The clinicopathological scoring system included nodal 
status of primary, length of disease free survival between primary 
cancer detection and detection of metastases, the number of hepatic 
tumours, size of the largest tumour and pre-operative CEA levels. 
Such a system had been shown if low (1-2) to predict a 60% chance 
of long term survival and if high to predict a 15% long term survival. 
The most commonly altered regions of the 50 cancers analysed were 
gains of 7p,7q, 8q, 13q and 20q and losses of 4p, 4q, 8p, 17p, 18p, 
18q and 22q  (all >50% analysed samples). Statistical analysis 
showed that the total fraction of the genome altered (FGA) was 
significantly associated with overall survival as was the clinically 
derived risk score. For those samples with >20% of the genome 
altered there was a median 38 month survival as compared with 18 
months for those with <20% FGA. Differences for disease free 
survival did not reach significance. If the total number of 
chromosomal areas altered was substituted for FGA this also was 
significantly related to overall survival. No individual chromosomal 
arm or clone was an independent predictor of overall or disease free 
survival when analysed together with the clinical risk score or FGA. It 
was increased FGA that was associated with improved survival and 
they postulate that too great a rate of genomic instability may render 
a cell unviable. It may also be that MSI-CIN- cancers have a poor 
prognosis. Risques et al (2003) reported a subset of diploid MSI 
stable cancers with poor prognosis. Previous reports have generally 
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shown greater genomic alteration to be associated with poor 
outcome (Arribas et al 1997, Weber et al 2001, De Angelis et al 
2001, Zhou et al 2002, Bajan et al 2002, Choi et al 2002, Diep et al 
2003, Knosel et al 2003). However, other reports do not confirm this 
(Kochar et al 1997, Crowe et al 2001, Scott et al 1998, Flyger et al 
1999, Geido et al 2002). Rooney et al (2001) also showed an 
increased number of chromosomal arm abnormalities to correlate 
with improved survival. Scott et al (1988) did not observe an increase 
in aneuploidy in higher stage cancers and observed a decrease in 
DNA index in lymph node metastases. 
Diep et al (2006) performed a meta-analysis in order to try and 
ascertain the relation between different chromosomal changes and 
the point in tumorigenesis that such changes developed. Losses of 
17p and 18 and gains of 8q, 13q and 20 were determined to be early 
changes. Loss of 4p was associated with progression of Dukes A to 
B/C/D. Loss of 8p and gain of 7p and 17q were associated with liver 
metastases. Loss of 14q and gains of 1q,11,12p and 19 were late 
events. 
 
Cardoso et al (2006) in a systemic review of the available aCGH data 
made the following observations. The percentage of aneuploid 
events observed at different stages increased from benign to more 
malignant histological states. Common losses occurred at 
chromosomes 4,5,7,8,18 and 20 and gains at 7,8,13 and 20. These 
seemed to be found fairly early in progression but increased in their 
relative representation as tumours progressed from adenomas to 
cancers to metastatic cancers. Some changes, however, such as 
those related to chromosome 1 seemed to become less frequent as 
the cancer progressed.  
 
In summary, ideally a larger sample size of Dukes B cancers would 
have been tested as after dividing into groups according to MSI 
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status the groups, despite our power calculation result, may be too 
small to show differences. There was difficulty in obtaining Dukes B 
DNA with the necessary length of follow up, also difficulty in 
procuring sufficient arrays for a larger analysis. And further, a lack of 
sufficient follow-up data for the Leeds samples as earlier described. 
Alternatively, despite the findings of differences between outcome 
groups for 18q LOH in previous studies, there may not be great 
difference between outcome groups in terms of copy number 
assessable by aCGH.  
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Chapter 6. 
In Situ Hybridisation (ISH) Analysis 
of Candidate Genes 
 
6.1 Introduction 
One method of searching for new genes related to colorectal cancer 
consists of using array CGH to identify small areas of genomic gain 
and then using the human genome map to identify genes within 
those areas that might be candidates for tumour involvement. 
Expression of these genes can then be assessed using in situ 
hybridisation (ISH).  
Our laboratory had analysed more than 200 colonic cancers and 
colonic cancer cell lines with aCGH and determined many small 
areas of gain and loss (<10Mb). This combined with analysis of 
individual BAC gain and loss allowed the identification of those small 
areas most often gained. Sometimes small areas of gain in a specific 
cancer corresponded to larger more frequent areas of gain in the set 
as a whole. For example we identified a small area of 13q which was 
gained in only 2 cancers, but gain of the whole of 13q was a common 
finding. Many of these areas proved to be too gene rich for easy 
selection of candidate genes for in situ analysis. Therefore a balance 
was struck in choosing regions for further analysis between the 
frequency of change and the gene density of the area. The four 
genes ultimately chosen from  the long list were chosen in an 
arbitrary way by Professor Ian Tomlinson, all of the long list choices 
would have been reasonable choices for research but we only had 
resources to research four. 
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A long list of genes for possible investigation was made (Table 6.1) 
and four genes chosen for further analysis with ISH: CDX2, FLT1, 
ARHGEF4 and RHOA.  
 
 
 
Having identified candidate genes ISH experiments were performed 
on various tissue types to gauge whether those genes were likely to 
be abnormally expressed in colorectal cancer. The probes were 
prepared by me and the in situ work undertaken by the 
Histopathology Unit (Professor Richard  Poulsom) at Cancer 
Research UK, Lincoln’s Inn Field, London. 
We had access to a tissue array- an array composed of 119 2mm  
cores of colon cancer tissue- this allowed investigation of multiple 
cancers’ expression of a gene in a single experiment. 
Table 6.1 ‘Long list’ of possible candidate genes (actual choices 
underlined) 
 
2: 131-133 especially 130.7-132.3 RAB6C, MAP3K2, CFC-1, PTPN18, ARHGEF4, 
TUBA2 
2: 188-221 esp.189-191.5 COL3A1, DIRC1, PMSI, GDF8, INPPI 
7: 99.3-99.7   COPS6, MCM7, TAF6, PILRB 
8: 144.2-145.3   RIGE, GLI4, RHOA 
9: 130-132.6 DDX31, CRSP8, BARHL, TSC1, RPL7A 
10: 76-82 esp. 79.8-80.7 DLG5, PPIF 
13: 25-27.5 esp. 26-26.2 GTF3A, POLRID, GSH1, CDX2, FLT3, FLT1 
17: 35-38 esp. 35.8-37.8 AATF, TBCID3, PIP5K2B 
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6.1.1 CDX2 
CDX2 is a homeobox transcription regulation gene and plays a major 
role in development especially in the gut and may also acts as a 
tumour suppressor in the adult colon. Chawengsaksophak et al 
(1997) made Cdx2 null mutant mice. Homozygous Cdx2-/- embryos 
died at implantation. Heterozygotes had multiple polyp-like lesions 
with the highest frequency in the caecum, decreasing in incidence 
both proximally and distally but involving the whole of the intestinal 
region which expresses CDX2 during development. Lesions did not 
occur elsewhere in the intestinal tract. Histologically, the polyps 
contained normal gastric mucosa with Paneth cells interposed 
proximally and distally between the stomach mucosa and the 
surrounding colonic epithelium. The gastric mucosa was arranged in 
an orderly array passing from stratified squamous epithelium of 
forestomach-type through mucous glands of the cardia to gastric 
glands of the corpus and finally to mucous antral-type cells as one 
passes both proximally and distally. This phenotype represented an 
anterior homeotic shift in which intestinal epithelium had the 
character of a more rostral phenotype due to localised areas of Cdx2 
haplo-insufficiency. The “default” state was forestomach epithelium 
which in the normal animal did not express CDX2. Intercalary growth 
subsequently resulted in the orderly appearance of the appropriate 
tissue types to “fill in” the histological discontinuity between gastric 
and colonic epithelia.The Cdx2 “knock out” studies detailed above 
showed that this gene is central to differentiation of midgut 
endoderm. They led to the conclusion that decreased levels of Cdx2 
expression resulted in rostralisation of gut differentiation with gastric 
mucosa constituting the “default” condition in which there was no 
expression of CDX2.  
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While CDX2 mutations predisposing to sporadic CRC have not been 
identified (Woodford-Ritchens et al 2001, Sivagnanasundaram et al 
2001) some polymorphism related to this gene has been (Rozek et al 
2005). As stated, most evidence suggests a role for CDX2 as a 
tumour suppressor gene, if it plays a role at all in cancer 
development. Expression of CDX2 does not seem to correlate to 
cancer stage, but does seem to correlate with tumour location (right 
sided), poor differentiation, high microsatellite instability status, and a 
positive first-degree family history (Rozek et al 2005). There is some 
evidence to suggest the importance of the microenviroment in 
relation to expression (Benahmed et al 2007). The regulation of 
CDX2 by the microenvironment might be relevant during the process 
of metastatic dissemination when the gene is transiently turned down 
in invasive cells.  
To understand the functional contributions of CDX2 to colon cancer, 
one group disrupted CDX2 in LOVO and SW48 human colon cancer 
cell lines by targeted homologous recombination. Consistent with the 
literature, disruption of CDX2 enhanced anchorage-dependent cell 
proliferation. However, homozygous loss of CDX2 led to significant 
inhibition of anchorage-independent growth in LOVO cells, and cell 
lethality in SW48 cells. Further analyses revealed that disruption of 
CDX2 led to anchorage-independent G1 to S growth arrest and 
anoikis. In vivo xenograft studies confirmed that disruption of CDX2 
inhibited LOVO tumour growth. These data demonstrated that CDX2 
mediates anchorage-independent growth and survival. Thus, CDX2 
may have tumorigenic potential in the human colon cancer cell lines 
LOVO and SW48 (Dang et al 2006).  
Witek et al (2005) showed over expression of CDX2 by human 
colorectal tumours compared with matched normal mucosa. They 
found that >80% of colorectal tumours over expressed mRNA and 
protein compared with normal mucosa. 
 
6.1.2 FLT1 
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FLT1 codes for a vascular endothelial growth factor (VEGF) receptor. 
Vascular endothelial growth factor (VEGF) is associated with tumour 
angiogenesis and poor prognosis in human colorectal cancer (CRC). 
VEGF receptor-1 (VEGFR-1 or FLT-1) is a high-affinity receptor for 
VEGF and is typically considered specific to endothelial cells. Fan et 
al (2005) reported the expression and function of FLT1 in CRC cell 
lines. FLT1 was expressed in all CRC cell lines studied as 
determined by RT-PCR, Western blot analysis, FACS, and ELISA. 
Treatment of the human CRC cell lines HT-29 and SW480 with 
VEGF-A (a ligand for both FLT1 and -2) or VEGF-B (a ligand specific 
for FLT1) led to activation of Erk-1/2, SAPK/JNK, and translocation of 
the p65 subunit of nuclear factor-kappaB into the nucleus. Both 
VEGF-A and -B led to significant induction of cell motility and 
invasiveness of CRC cells. Stimulation of cells with VEGF-A or -B 
also led to larger and more numerous colonies in soft agar. However, 
activation of FLT1 did not increase CRC cell proliferation. In contrast 
to the previous paradigm that VEGFRs are not present on tumour 
cells of epithelial origin, they found that FLT1 was present and 
functional on CRC cells, and activation by VEGF family ligands could 
activate processes involved in tumour progression and metastasis. 
 
 Lesslie et al (2006) investigated the role of Src family kinases 
(SFKs) in VEGF-mediated signalling in CRC cell lines. Their results 
suggested that FLT1 promoted migration of tumour cells through a 
Src-dependent pathway linked to activation of focal adhesion 
components that regulate this process.   
 
Further research (Yamaguchi et al 2007) based on sFLT1 levels in 
colorectal cancer without distant metastases showed patients with 
higher sFLT1 levels demonstrated significantly longer recurrence-
free survival than patients with lower sFLT1 levels. The FLT1 gene 
encodes for both the full-length receptor FLT1 (VEGFR-1) and a 
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soluble form designated sFLT1. SFLT1 carries the VEGF-binding 
domain of FLT1 as well as a 31-amino-acid stretch derived from an 
intron and tightly binds VEGF, suppressing its angiogenic activity.  
Multivariate analysis showed that the sFLT1 levels in cancer tissue 
were an independent prognostic indicator of disease progression. 
SFLT1 expression was significantly elevated in colorectal cancer 
tissue compared with normal mucosa and the intratumoral balance 
between sFLT1 and VEGF was significantly different between tumour 
tissue and normal controls. Furthermore, sFLT1 levels showed a 
significant prognostic value.  
 
 
6.1.3 ARHGEF4 
 
ARHGEF4 - also called APC-stimulated guanine nucleotide 
exchange factor (ASEF) and GEF4- codes one of the Rho family 
guanine nucleotide exchange factors (GEFs) which are essential 
links between extracellular signalling events and the activation of 
Rho family GTPases, acting as the direct facilitators of GDP 
displacement in these molecular switches (Hamann et al 2007). The 
GTP-loaded and activated Rho family GTPases, such as RHOA, 
RAC1, and CDC42, have classically been appreciated for their 
effects on cytoskeletal reorganization and the establishment of 
cellular polarity  but also are known to induce proliferative responses 
through the binding and activation of proteins such as p21-activated 
kinase (PAK) and Rho associated kinase. Despite the potential for 
direct, unregulated cellular proliferation and metastasis through 
constitutive activation of Rho family GTPases, activating mutations 
similar to those established for Ras have not been discovered in 
human cancers. Therefore, Rho family GEFs are frequently 
investigated in terms of their potential as oncogenic triggers, since 
they are the first upstream activators of Rho-GTPases and potentially 
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misregulate GTPases when over expressed or mutated to 
constitutively active forms.  
 
ARHGEF4 was first identified through a yeast two-hybrid screen 
using the APC armadillo repeat region (APCARM) as bait. APCARM 
is an important segment of APC and is retained in APC truncation 
mutations found in colorectal cancers and FAP. Although its exact 
function remains elusive, the APCARM interaction localized to an 
APC binding region (ABR) within ARHGEF4, a region lying 
immediately N-terminal to the protein’s Src-homology 3 (SH3) 
domain. The most profound outcome of the APC-ARHGEF4 
interaction is that it stimulates GEF activity, leading to Rac1 
activation, lamellipod formation, and increased cell migration.  
 
Kawasaki et al (2003) found evidence suggesting that the APC-
ARHGEF4 complex functions in cell migration as well as in E-
cadherin-mediated cell-cell adhesion, and that truncated APC 
present in colorectal tumour cells contributes to their aberrant 
migratory properties. It has therefore been suggested that the 
truncated forms of APC often found in colorectal cancer and FAP are 
not only devastating due to unregulated cellular β-catenin 
accumulation but may also enhance cellular metastasis due to 
constitutive ARHGEF4 activation. 
 
Mitin et al (2007) showed that binding of the armadillo repeats of 
APC to a 'core APC-binding' (CAB) motif within ARHGEF4, or 
truncation of the SH3 domain of ARHGEF4, relieves auto inhibition, 
allowing the specific activation of CDC42. Structural determination of 
auto inhibited ARHGEF4 revealed that the SH3 domain forms an 
extensive interface with the catalytic DH and PH domains to obstruct 
binding and activation of CDC42, and the CAB motif is positioned 
adjacent to the SH3 domain to facilitate activation by APC. In 
colorectal cancer cell lines, full-length, but not truncated, APC 
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activates CDC42 in an ARHGEF4-dependent manner to suppress 
anchorage-independent growth. The authors therefore proposed a 
model in which ARHGEF4 acts as a tumour suppressor when 
activated by APC and inactivation of ARHGEF4 by mutation or APC 
truncation promotes tumorigenesis. 
 
 
6.1.4 RHOA 
 
RHOA codes a GTPase which is related to rearrangement of the 
actin cytoskeleton. This process is primarily controlled by the 
members of Rho small GTPase family (Chang 2006), including 
RHOA, RAC1, and CDC42. Like other small GTPases, Rho 
GTPases cycle between inactive GDP-bound and active GTP-bound 
forms. Activation of Rho GTPases is stimulated by guanine 
nucleotide exchange factors and inhibited by GTPase-activating 
proteins. On activation, Rho GTPases recruit effector proteins to 
regulate the actin cytoskeleton. In epithelial cells, Rho GTPases are 
implicated in regulating morphology and adhesion because 
interactions between the actin cytoskeleton and adherens junctions 
determine cell shape and motility. Formation of adherens junctions 
promotes cell-cell adhesion and is important in organizing normal 
epithelial sheets. Adherens junctions consist of the transmembrane 
protein E-cadherin, whose cytoplasmic domain interacts with h-
catenin, which binds α-catenin. Because formation of adherens 
junctions is associated with actin dynamics, RAC1 and CDC42 
activity are required for the formation and maintenance of E-cadherin 
mediated adherens junctions. Although a basal level of RHOA 
activity is also necessary for adherens junction formation, high RHOA 
activity disrupts the formation of adherens junctions. On the other 
hand, E-cadherin-mediated formation of adherens junctions strongly 
inhibits RHOA activity but increases activities of both RAC1 and 
CDC42.  
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Up-regulation of small GTPases, RHOA and RHOC, is associated 
with tumour 
progression in ovarian carcinoma (Horiuchi et al 2003). Analysis of 
mRNA levels of the RHO family genes revealed that levels of both 
RHOA and RHOC were significantly higher in carcinomas than in 
benign tumours.  
 
Arango et al (2005) showed that RHOA expression was significantly 
related to survival for Dukes C cancers. Using immunohistochemistry 
and a tissue array containing 137 Dukes C cancer samples they 
found that reduced RHOA expression was associated with 
significantly shorter survival. 
 
 
 
6.2     In Situ Hybridisation Results 
6.2.1  ISH results in general 
ISH was performed on sections of various tissue types to assess the 
behaviour of the probes.  In order to establish that there was 
adequate preservation of mRNA in the blocks from which the 
sections were derived, the levels and patterns of expression of β-
actin mRNA were assessed.  Tissues from all cases revealed 
expression of β-actin mRNA, with expected patterns of expression; 
increasing in strength towards the luminal surface in the epithelium of 
normal crypts and with the strongest signals in lymphoid aggregates 
where present. 
ISH using the 4 test probes gave expression results consistently only 
for CDX2. There was some expression seen for the FLT1 and RHOA 
probes but to a lesser degree. ARHGEF4 did not show meaningful 
levels of expression (detectable above background). 
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To assess CDX2 expression, a variety of tissue sections were 
probed: sections of Crohn’s disease small bowel tissue revealed 
expression in the normal crypt epithelium, and, as expected , not in 
the regions of pseudopyloric metaplasia (Figure 6.1 a).  Hybridisation 
to Barrett’s oesophageal/gastric tissue with colonic type metaplasia 
revealed expression of CDX2 mRNA in the metaplastic tissue alone 
(Figure 6.1 b,c). For human villiform intestinal foetal tissue (12.4 
weeks) strong CDX2 expression was seen (Figure 6.1 f).  In colonic 
cancer tissue (Figure 6.1 d) fairly homogenous expression was seen 
within the cancer epithelium as well as in adjacent normal crypts.  
However, there seemed to be some loss of CDX2 mRNA expression 
at the invasive edge of the cancer. Normal adjacent crypts showed 
no weakness of expression at the base, although analysis of normal 
colonic mucosa (Figure 6.1 e) showed some weakness of expression 
at the bottom of crypts.  
Drawing on the results of Witek (Witek et al (2005)) who showed over 
expression of CDX2 by human colorectal tumours compared with 
matched normal mucosa we probed the tissue array to see if we 
could relate CDX2 expression to outcome. We found variable CDX2 
mRNA expression strength for the cancers analysed and therefore 
results for this array were scored (Figure 6.1 j, k,l) (see next section). 
RHOA expression was seen for foetal kidney tissue (Figure 6.1 i). 
Foetal gut did not show convincing RHOA expression. Expression on 
the tissue array was highly variable but very low level and scoring  
was not attempted.  
ARHGEF4 expression was weakly positive for foetal gut but ‘spotty’ 
in a distribution suspected to be due to eosinophils. For the tissue 
array ARHGEF4 expression was spotty and this again suggested 
expression due to eosinophils.  
FLT1 expression was seen clearly on kidney tissue (Figure 6.1 h) 
and for joint tissue (Figure 6.1 g). FLT1 expression was always 
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related to endothelial tissue. FLT was also seen related to clusters on 
small vessels in foetal gut (not shown). Although the tissue array 
produced expression data such expression related to endothelial 
tissue and was not cancer specific.  
 
 
 
 
Figures 6.2 a-l . Results of ISH experiments 
a). 
                        
 Small bowel Crohns CDX2 x10  br                 Small bowel Crohns CDX2 x10  dk    
 
b).                                             
                        
Barretts oesophageal/gastric tissue             Barretts oesophageal/gastric tissue  
with colonic type metaplasia (i)                  with colonic type metaplasia (i)   
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CDX2 x20 bright                                                                   CDX2 x20 dark 
 
 
 
c). 
                        
Barretts oesophageal/gastric tissue          Barretts oesophageal/gastric tissue  
with colonic type metaplasia  (ii)               with colonic type metaplasia (ii)   
CDX2  x20 br                                                    CDX2  x20 dk 
d).     
                          
Colonic cancer CDX2 x20 br                         Colonic cancer CDX2 x20 dk   
e). 
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Normal colonic mucosa CDX2 x20 br        Normal colonic mucosa CDX2 x20 dk   
 
 
f). 
                       
Normal villiform intestinal foetal tissue  Normal villiform intestinal foetal tissue 
12.4 weeks CDX2 x20 br                              12.4 weeks CDX2 x20 dk   
 
g). 
                       
 Joint FLT1 x20 br                                        Joint FLT1 x20 dk   
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h).   
                                     
Kidney FLT1 x20 br                                      Kidney FLT1 x20 dk 
 
i). 
                         
Foetal kidney RHOA x20 br                          Foetal  kidney RHOA x20 dk 
 
 
j). 
                         
CDX2  grade 3 scoring example                       CDX2 grade 3  scoring example 
colonic cancer array x 20 br                             colonic cancer array  x 20 dk 
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k). 
                          
CDX2  grade 2 scoring example                   CDX2 grade 2  scoring example 
colonic cancer array x 20 br                         colonic cancer array  x 20 dk  
l). 
                             
CDX2  grade 1 scoring example                   CDX2 grade 1  scoring example 
colonic cancer array x 20 br                         colonic cancer array  x 20 dk  
 
6.2.2  Tissue array CDX2 expression results.  
The tissue array was composed of 119 cancers of which 106 had 
associated patient outcome data. I reiterate that this collection of 
cancers was completely different to that used in previous 
experiments. We used the tissue array for the opportunistic reason 
that it had been already constructed , was available and allowed 
testing of multiple colorectal cancers in a single ISH experiment. 
84(79.2%) were associated with >5 year patient survival and 
22(20.7%) with patient death within 5 years of operation. Comparing 
background clinicopathological data for these groups (Table 5.2) 
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showed no statistically significant difference between the groups for 
age, gender, Dukes stage and grade. The proportion of T4 cancers 
was significantly different between the groups (>5 year survival 
33.3% versus < 5 year survival 63.6% p=0.014). 
Due to the failure of appropriate expression for the other three genes 
only CDX2 expression was scored using data from the tissue array 
experiment. Scoring of expression was 1, 2 or 3 with 3 being the 
strongest expression (Figure 6.1 j,k,l). Scoring was under taken by 
me with Professor Richard Poulsom verifying the scoring system 
used. For those cancers from patients with < 5 years survival scores 
were 1=4 (18.2%), 2=10 (45.4%), 3=8 (36.4%) versus  1=24 (28.6%), 
2=29 (34.5%), 3=31 (36.9%) cancers related to >5 year survival. 
There was no significant relationship found between CDX2 
expression and survival. Also, using a Chi-squared test for trend, the 
relationship between Dukes stage and CDX2 expression was tested 
and no significant relationship found (p = 0.52). 
 
 
Table 6.2  Comparison of clinopathological factors for tissue 
array outcome groups 
                             5 year survival            < 5 year survival    p 
Number                     84                            22 
Age                                     69.7                         66.8              0.78 
Gender  (Female)             44 (52.3)                 11 (50)    1.0 
Stage     T1                         2 (2.4)                       0 (0)       1.0 
               T2                         9 (10.7)                     0 (0)        0.2 
               T3                       45 (53.6)                   8 (36.4)    0.23 
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               T4                       28 (33.3)                 14 (63.6)       0.014* 
Dukes Stage 
                A                        9 (10.7)                    0 (0)           0.2 
                B                       53 (63)                   12 (54.5)   0.47 
                C                       22 (26.2)               10 (45.4)    1.0 
Grade    
             Well                      32 (38)                   5 (22.7)       0.22 
             Mod                      47 (56)                   16(72.7)        0.22  
             Poor                      5  (5.9)                  1 (4.5)                  1.0                
 
CDX2 Expression 
              1                     24 (28.6)            4 (18.2)                0.42           
              2                    29 (34.5)         10 (45.4)              0.46 
              3                    31 (36.9)           8 (36.4)               1.0           
 
6.3  Discussion 
For CDX2 it remains unclear from our work whether the finding of 
reduced CDX2 expression related to the invading edge in cancer 
represents an important finding suggestive of a role for reduced 
CDX2 expression in relation to local invasion. 
The gene was selected on the basis of an area of gain found on 
chromosome 13 with aCGH so we were expecting a gain in 
expression related to a gain in copy number rather than an effect 
related to reduced expression. 
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 The loss of expression from the deepest invasive cellular layer might 
suggest the commencement of a possible change of cell type. An 
alternative explanation of this finding is provided by the fact that 
some normal crypts seem to have lost expression of CDX2 at the 
bottom of the crypts and that this loss of expression seen in cancer 
tissue simply mirrors that seen in normal tissue and is of no 
pathological significance. As the introduction to this chapter shows 
there is data suggesting that CDX2 may be important in maintaining 
the commitment to small and large intestinal lineages, we are unable 
to make definite conclusions. The attempt to correlate CDX2 
expression to outcome did not produce a significant result.  
RHOA and ARHGEF4 produced no results of significance. It may be 
that there is increased expression of either gene in CRC but we did 
not show this with the probes used. This is particularly true of 
ARHGEF4 were eosinophilic expression was detected; this might be 
due to the presence of particular ‘sticky’ probe domains. Given the 
finding of RHOA expression correlating with Dukes C survival when 
expression was assessed using immunohistochemistry one might 
have hoped our experiments to have produced more conclusive 
results. The probe undoubtedly worked but we could not replicate the 
relation to prognosis found by Arango (Arango et al 2005). 
As FLT1 codes for a receptor the expression results are difficult to 
interpret. It is difficult to know what purpose an isolated increase in 
FLT1 gene expression would serve in the context of tumour 
progression. One could conceive of an observed increase in receptor 
numbers related to an increase in endothelial cell numbers. That 
could be checked by counting vessels in sections stained with for 
example CD31.  
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7. Analysis of Sporadic Adenomas 
with Array Comparative Genomic 
Hybridisation 
7.1 Introduction.  
 
 
As discussed in the introduction (1.2.1 and 1.2.2) the timing and form 
of CIN in CRC have not yet been determined. In this part of the 
study, the aim was to examine the evidence for chromosomal-scale 
changes in colorectal adenomas (CRA) using aCGH. We deliberately 
analysed lesions that had grown and/or progressed from the very 
small, mildly dysplastic stage, so as to increase the chances of 
detecting genetic changes (this work was included in the publication 
Jones et al (2007).  At the time of designing this work no work 
existed using aCGH to investigate adenomas. 
 
All adenomatous tissue came from Oxford and was processed in the 
same way as the cancer tissue described earlier. Adenomas were 
snap frozen and stored with paired normal tissue at -70 C. DNA was 
extracted as previously described (2.1). Adenomas were examined 
histopathologically and for MSI status and ploidy (2.3, 2.4, 2.5).Then 
examined with aCGH (2.6). 
 
7.2 Results. 
Adenoma characteristics. 
All 14 polyps were greater than 1cm in size. 12 were mild or 
moderately dysplastic with 2 severely dysplastic. 11 polyps were 
tubular adenomas and 3 were tubulovillous adenomas. All tissue 
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from which DNA was derived was confirmed as containing at least 
60% adenomatous tissue by Professor Mohammad Ilyas. 
MSI and ploidy. 
No adenomas showed MSI on examination with the markers BAT 26 
and D5S346. All adenomas were diploid on FACS analysis. 
 
aCGH 
Appendix 11 gives a summary of the aCGH findings. Changes were 
found in 10 cases. 6 cases had 1-3 changes, 2 had 4 changes and 1 
had 12 changes and 1 had 13 changes. Of 44 chromosmal scale 
changes 12 involved the whole chromosome. There were more 
losses than gains (38 versus 6). The median number of gains was 0 
(range 0-4). The median number of losses was 1 (range 0-12). 
Commonest changes seen were for 1p loss (57%), 17p loss (50%), 
19 loss (28.6%), 13 gain (21.4%), and 22 loss (21.4%). 
 
7.3 Discussion 
We have found that a small number of large-scale genetic changes 
can be detected by aCGH in the majority of adenomas from sporadic 
cases. Whilst our adenomas were not ‘early’ lesions based on their 
size, all were scored as near-diploid by flow cytometry.The most 
frequent regions of change that we have found in our adenomas are 
similar to those found by Cardoso et al (2006), with the exception 
that chromosome 7 was not commonly gained in our series. 
Interestingly some changes - such as the deletion of chromosome 
18q – that are thought to be present in early carcinomas (Hermsen et 
al 2002) were almost absent in the adenomas. Also most aCGH 
changes involved the smaller chromosomes, suggesting that these 
may have been tolerated as ‘background’ changes that produced no 
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great selective advantage or disadvantage. We would have liked to 
investigate more adenomas but the number of aCGH arrays 
available was limited. 
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8. Conclusions and Future 
Research Directions 
Whilst we have not found differences between good and bad 
outcome Dukes B cancers that could be usefully used to predict 
prognosis because such differences as have been detected are only 
seen in few cancers, and not discovered evidence for a new gene of 
significance in relation to CRC, the techniques used remain valid in 
the search for answers to the questions addressed. 
I have completed the analysis that was originally planned, collecting 
sufficient Dukes B cancers to meet the power calculation and 
performing all planned experiments on these with technical success. 
The work has yielded new areas of small gain and loss that could be 
investigated for new genes of importance in colorectal cancer. Also I 
have identified areas of copy number change in sporadic adenomas. 
 In terms of finding new genes of interest, the areas we have 
investigated contain many genes and continued investigation of 
these areas with immunohistochemical staining, were antibodies 
against proteins related to genes of interest are available, and ISH 
may yield results of interest. 
The fact that 18q LOH has been shown to have prognostic ability 
gives rise to optimism that there is a difference between good and 
bad outcome cancers in terms of the factors measurable with aCGH. 
It may also be seen that outcome difference has been shown 
between MSI positive and negative cancers and CIN positive and 
negative cancers. It is probable that if a sample set associated with 
sufficiently high quality pathology, clinical and follow up data could be 
collected in sufficient numbers results of value might be produced. 
The use of the newer commercially available oligonucleotide arrays 
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will be helpful in terms of array availability and increased ease of 
usage.  
Genes within the small areas of gain could be correlated with the 
results of large gene linkage studies such as the CORGI trial to ty 
and identify the true genes of interest in these areas. 
In terms of the timing of CIN the adenoma work could be repeated 
using SNP arrays in the hope a identifying those genes exhibiting 
copy number change at the earliest stage. This would involve the 
microdissection of individual aberrant crypts and the extraction of 
DNA from these small entities which constitute the earliest 
histologically observable changes. 
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12. Appendices.
1 . Sequences, and reaction conditions for the PCR primers used in PCR
experiments.
Name Primer sequence Product [MgCl]
Annealing
temp
D5S346
F [6-FAM]actcactctagtgataaatcggg
96-122
bp 2.5 uM 55oC
D5S346
R agcagataagacagtattactagtt
BAT26 F [6-FAM]tgactacttttgacttcagcc
80-100
bp 2.5 uM 60oC
BAT26 R aaccattcaacatttttaaccc
2. MSI and LOH results compared for 5 year survival groups
Survival >5 year <5 year                     p
MSI (%) 8/43(18) 6/36 (16.7) 1.0
BAT 26 (%) 8/43(18) 3/36 (8.8) 0.31
D5S346 LOH 20 8
MISMATCH 1 2
MSI 0 3
NI 6 4
NL 16 17
% INFORMATIVE 55.6 32 0.17
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3. Comparison of ploidy for survival groups.
Survival >5 years <5 years p
Aneuploid (%) 10(43.5) 15(55.6) 0.57
Tetraploid (%) 1(4.3) 1(3.7) 1.0
Diploid (%) 12(52.2) 11(40.7) 0.57
4. Summary of genomic gain/loss by chromosome for the different
survival/MSI subgroups.
5yr+/MSI- 5yr+/MSI+   5yr+     5yr-/MSI- 5yr-/MSI+    5yr-
Chr1 0 0 0 0 0 0
Chr arm 1 0 1 1 1 2
Large gain 6 0 6 4 0 4
Small gain                                  3             0              3 3 0 3
<10Mb
Gain++ 1 0 1 2 0 2
Chr2 5              0 5 4 0 4
Chr arm 2 0 2 0 0 0
Large gain 4 0 4 2 0 2
Small gain 0 0 0 2                0 2
<10Mb
Gain++ 2              0              2              2              0 2
Chr3 2 0 2 1 0 1
Chr arm 1 0 1 1 0 1
Large gain 4              0 4 0 0 0
Small gain 1 0 1 1 0 1
<10Mb
Gain++ 1              1 2 0 0 0
Chr4 2 0 2 0 0 0
Chr arm 1 0 1 0 0 0
Large gain 1 0 1 1 0 1
Small gain 0 0 0 0 0 0
<10Mb
Gain++ 0 0 0 1 0 1
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Chr5 3 1 4 0 0 0
Chr arm 5 2 7 2 0 2
Large gain 1 0 1 3 0 3
Small gain 0 0 0 1 0 1
<10Mb
Gain++ 1 0 1 0 0 0
Chr6 6 0 6 5 2 7
Chr arm 1 0 1 2 0 2
Large gain 1 0 1 3 1 4
Small gain 0 0 0 1 0 1
<10Mb
Gain++ 0 0 0 2 0 2
Chr7 16 2 18 11 1 12
Chr arm 2 0 2 1 0 1
Large gain 1 1 2 0 0 0
Small gain 0 1 1 3 0 3
<10Mb
Gain++ 1 2 3 1 0 1
Chr8 3               0 3 2 1 3
Chr arm 17 2 19 14 3 17
Large gain 0 0 0 2 0 2
Small gain 0 0 0 1 0 1
<10Mb
Gain++ 3 1 4 1 1 2
Chr9 4 0 4 6 0 6
Chr arm 0 0 0 0 0 0
Large gain 4 1 5 1 0 1
Small gain 1 0 1 1 0 1
<10Mb
Gain++ 0 0 0 0 0 0
Chr10 6 1 7 9 1 10
Chr arm 1 2 3 0 0 0
Large gain 2 0 2 1 0 1
Small gain 1 1 2 2 0 2
<10Mb
Gain++ 1 1 2 2 0 2
Chr11 6 0 6 3 0 3
Chr arm 3 0 3 1 0 1
Large gain 3 1 4 4 1 5
Small gain 0 0 0 0 0 0
<10Mb
Gain++ 3 0 3 0 0 0
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Chr12 4 0 4 4 0 4
Chr arm 1 0 1 2 0 2
Large gain 1 0 1 1 1 2
Small gain 1 0 1 2 0 2
<10Mb
Gain++ 0 0 0 1 1 2
Chr13 26 2 28 20 2 22
Chr arm 0 0 0 1 0 1
Large gain 0 0 0 0 0 0
Small gain 1 0 1 1 0 1
<10Mb
Gain++ 0 0 0 6 2 8
Chr14 1 0 1 2 0 2
Chr arm 0 0 0 0 0 0
Large gain 0 0 0 0 0 0
Small gain 0 0 0 0 0 0
<10Mb
Gain++ 1 0 1 0 0 0
Chr15 2 0 2 2 0 2
Chr arm 0 1 1 1 0 1
Large gain 0 0 0 0 0 0
Small gain 1 0 0 0 0 0
<10Mb
Gain++ 0 0 0 0 0 0
Chr16 6 0 6 0 1 1
Chr arm 2 0 2 1 0 1
Large gain 1 0 1 1 0 1
Small gain 0 2 2 0 0 0
<10Mb
Gain++ 0 1 1 0 0 0
Chr17 0 0 0 0 0 0
Chr arm 4 3 7 6 0 6
Large gain 2 0 2 0 0 0
Small gain 1 1 2 0 0 0
<10Mb
Gain++ 0 1 1 0 0 0
Chr18 1 1 2 0 1 1
Chr arm 1 2 3 1 1 2
Large gain 0 0 0 1 0 1
Small gain 0 1 1 0 0 0
<10Mb
Gain++ 0 1 1 1 0 1
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Chr19 6 0 6 8 1 9
Chr arm 1 0 1 0 0 0
Large gain 1 0 1 1 0 1
Small gain 0 0 0 0 0 0
<10Mb
Gain++ 0 0 0 1 0 1
Chr20 16 3 19 17 1 18
Chr arm 10 0 10 7 1 8
Large gain 2 0 2 0 1 1
Small gain 1 0 1              0 2 2
<10Mb
Gain++ 11 1 12 10 2 12
Chr21 8 2 10 7 2 9
Chr arm 0 0 0 0 0 0
Large gain 0 0 0 0 0 0
Small gain 0 0 0 0 0 0
<10Mb
Gain++ 0 0 0 0 0 0
Chr22 2 0 2 1 0 1
Chr arm 0 0 0 0 0 0
Large gain 1 0 1 0 0 0
Small gain 0 0 0 0 0 0
<10Mb
Gain++ 0 0 0 0 0 0
Loss
Chr 1 8 2 10 9 2 11
Chr arm 4 0 4 5 1 6
Large loss 17 0 17 10 2 12
Small loss 0 0 0 0 0 0
<10Mb
Loss++ 1 0 1 1 0 1
Chr 2 1 0 1 0 0 0
Chr arm 0 0 0 0 0 0
Large loss 3 0 3 1 0 1
Small loss 0 0 0 2 0 2
<10Mb
Loss++ 0 0 0 0 0 0
Chr 3 0 0 0 0 0 0
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Chr arm 0 0 0 3 0 0
Large loss 4 1 5 2 0 2
Small loss 0 0 0 0 0 0
<10Mb
Loss++ 0 0 0 0 0 0
Chr 4 3 0 3 8 0 8
Chr arm 1 0 1 1 0 1
Large loss 4 0 4 0 0 0
Small loss 0 0 0 0 0 0
<10Mb
Loss++ 0 0 0 0 0 0
Chr 5 1 0 1 2 1 3
Chr arm 3 0 3 2 0 2
Large loss 0 0 0 3 0 3
Small loss 0 0 0 0 0 0
<10Mb
Loss++ 0 0 0 0 0 0
Chr 6 6 1 7 0 0 0
Chr arm 1 0 1 3 0 3
Large loss 3 1 4 3 1 4
Small loss 0 0 0 0 0 0
<10Mb
Loss++ 0 0 0 0 0 0
Chr 7 1 1 2 0 0 0
Chr arm 1 0 1 2 0 2
Large loss 3 0 3 0 0 0
Small loss 1 0 1 0 0 0
<10Mb
Loss++ 0 0 0 0 0 0
Chr 8 1 1 2 0 0 0
Chr arm 15 1 16 14 3 17
Large loss 0 0 0 1 0 1
Small loss 0 0 0 0 0 0
<10Mb
Loss++ 0 0 0 0 0 0
Chr 9 8 1 9 7 2 9
Chr arm 0 0 0 1 1 2
Large loss 2 0 2 0 1 1
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Small loss 0 0 0 1 0 1
<10Mb
Loss++ 0 0 0 0 0 0
Chr 10 5 0 5 1 0 1
Chr arm 1 2 3 0 0 0
Large loss 2 0 2 0 0 0
Small loss 1 0 1 0 0 0
<10Mb
Loss++ 0 0 0 0 0 0
Chr 11 0 0 0 0 0 0
Chr arm 3 0 3 1 0 1
Large loss 3 1 4 3 0 3
Small loss 0 0 0 2 0 2
<10Mb
Loss++ 0 0 0 1 0 1
Chr 12 2 0 2 1 0 1
Chr arm 1 0 1 1 0 1
Large loss 0 0 0 1 1 2
Small loss 0 0 0 1 0 1
<10Mb
Loss++ 0 0 0 0 0 0
Chr 13 3 1 4 3 1 4
Chr arm 0 0 0 0 0 0
Large loss 1 1 2 0 0 0
Small loss 0 0 0 0 0 0
<10Mb
Loss++ 0 0 0 0 0 0
Chr 14 12 0 12 12 1 13
Chr arm 0 0 0 0 0 0
Large loss 1 0 1 0 0 0
Small loss 0 0 0 0 0 0
<10Mb
Loss++ 0 0 0 0 0 0
Chr 15 13 0 13 6 1 7
Chr arm 0 0 0 0 0 0
Large loss 1 0 1 1 0 1
Small loss 0 0 0 0 0 0
<10Mb
Loss++ 0 0 0 0 0 0
197
Chr 16 3 0 3 2 1 3
Chr arm 0 0 0 1 0 1
Large loss 1 0 1 0 1 1
Small loss 0 0 0 0 0 0
Loss++ 0 0 0 0 0 0
Chr 17 7 0 7 4 0 4
Chr arm 15 2 17 17 2 19
Large loss 1 0 1 0 0 0
Small loss 1 0 1 0 0 0
<10Mb
Loss++ 0 0 0 0 0 0
Chr 18 22 0 22 18 1 19
Chr arm 1 1 2 1 2               3
Large loss 1 0 1 1 0               1
Small loss 0 0 0 0 0 0
<10Mb
Loss++ 0 0 0 0 0 0
Chr 19 8 1 9 9 3 12
Chr arm 0 0 0 0 0 0
Large loss 0 0 0 0               0 0
Small loss 0 0 0 0 0 0
<10Mb
Loss++ 0 0 0 0 0 0
Chr 20 2 3 5 1 1 2
Chr arm 7 0 7 6 0 6
Large loss 1 0 1 0 0               0
Small loss 0 0 0 0 0 0
<10Mb
Loss++ 0 0 0 0 0 0
Chr 21 12 2 14 8 0 8
Chr arm 0 0 0 0 0 0
Large loss 1 0 1 0 0 0
Small loss 0 0 0 0 0 0
<10Mb
Loss++ 0 0 0 0 0 0
Chr 22 22 3 25 20 4 24
Chr arm 0 0 0 0 0 0
Large loss 1 0 1 0 0 0
Small loss 0 0 0 0 0 0
<10Mb
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Loss++ 0               0 0 0 0 0
5. Comparison of gains and losses by
survival/MSI groups
>5 year survival versus < 5 year
survival
Chromosome gain >5(43) % <5(36) % p Sig’
10 7 16.3 10 27.8 0.27
16 6 14.0 1 2.8 0.11
19 6 14.0 9 25.0 0.25
p arm section gain > 10Mb
5p 11 25.6 3 8.3 0.07
6p 8 18.6 12 33.3 0.19
12p 4 9.3 7 19.4 0.2
16p 9 20.9 2 5.6 0.06
q arm section gain > 10Mb
6q 6 14 9 25 0.27
9q 4 9.3 7 19.4 0.2
16q 7 16.3 2 5.6 0.17
Chromosome loss
4 3 7.0 8 22.2 0.1
6 7 16.3 0 0.0 0.014 *
14 12 27.9 13 36.1 0.47
19 9 20.9 12 33.3 0.3
21 14 32.6 8 22.2 0.33
22 25 58.1 24 66.7 0.49
p arm section loss >10 Mb
4p 3 7 9 25 0.03 *
5p 0 0 6 16.7 0.007 *
6p 10 23.3 3 8.3 0.12
10p 7 16.3 2 5.6 0.17
20p 14 32.6 7 19.4 0.2
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q arm section loss >10 Mb
5q 4 9.3 7 19.4 0.2
19q 11 25.6 13 36.1 0.34
21q 14 32.6 8 22.2 0.32
5+M- versus 5-M-
Chromosomal gain
10 6 17.1 9 30.0 0.25
16 6 17.1 0 0.0 0.027 *
p arm section gain >10 Mb
5p 8 22.9 3 10 0.2
6p 8 22.9 10 33.3 0.4
10p 7 20 10 33.3 0.57
16p 9 25.7 1 3.3 0.016 *
q arm section gain >10 Mb
9q 3 8.6 7 23.3 0.17
13q 25 71.4 18 60 0.43
16q 6 17.1 1 3.3 0.23
Chromosomal loss
4 3 8.6 8 26.7 0.09
6 6 17.1 0 0.0 0.027 *
10 5 14.3 1 3.3 0.21
p arm section loss >10 Mb
1p 28 80 21 70 0.4
3p 2 5.7 5 16.7 0.23
4p 3 8.6 9 30 0.05 *
5p 0 0 5 16.7 0.017 *
6p 8 22.9 3 10 0.2
10p 7 20 2 6.7 0.16
q arm section loss >10 Mb
15q 15 42.9 9 30 0.31
5+M+ versus 5-M+
Chromosome gain
20 3 37.5 1 16.7 0.58
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p arm section gain >10Mb
5p 3 37.5 0 0 0.2
6p 0 0 2 33.3 0.16
18p 2 25 0 0 0.47
q arm section gain >10Mb
6q 0 0 2 33.3 0.16
8q 2 25 3 50 0.58
17q 2 25 0 0 0.47
Chromosome loss
20 3 37.5 1 16.7 0.58
21 2 25 0 0.0 0.47
22 3 37.5 4 66.7 0.16
p arm section loss >10Mb
1p 2 25 4 66.7 0.28
6p 2 25 0 0 0.47
8p 2 25 3 50 0.58
18p 2 25 3 50 0.58
19p 1 12.5 3 50 0.24
20p 4 50 0 0 0.08
q arm section loss >10Mb
13q 2 25 0 0 0.47
16q 0 0 2 33.3 0.16
18q 0 0 2 33.3 0.16
19q 2 25 3 50 0.58
20q 3 37.5 0 0 0.2
21q 2 25 0 0 0.47
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6. Gains at specific BAC clone sites
>5yrMSI- >5yrMSI+ <5yrMSI- <5yrMSI+
chr 7 % 7 % 7 % 8q %
0-42.46 54.3 0-14.7 50 0-2.4 55.2 34.3-37 33.3
42.46-50.3 51.4 15.8-97.1 37.5 3.3-23.5 51.7 38.40.2 33.3
50.3-56.46 48.6 98.5-101 50 24.3-49.6 48.3 40.9-145.7 50
56.46 45.7 101-158.3 end 37.5 50.2-51.4 44.4 6 66.7
62.65-70.97 42.85 8q 52.3-56.4 41.4 0-54.7
70.97-76.8 45.7 48.3-65 25 56.4-67.4 37.9 56.7-75.9 33.3
77.5-158.28 48.6 65-142.3 37.5 68.1-158.3 41.4 76.5-170.5 50
8q 144.2-145.7 50 8q 20 33.3
0-36.17 20 145.7 37.5 40.2 24.2 0-9.2
36.17-37.14 25.7 5p 40.2 27.6 10.4-16.6 16.7
37.14 37.14 0-45.6 37.5 41.2-42.2 34.4 17.8-20.2 50
39.5-41.86 40 45.6-53.3 25 42.2-42.9 44.8 21.5-22.5 16.7
41.86 45.7 9 47.5-61.2 48.5 23.5-29.4 33.3
41.86-145.7 60 120.6-129.25 25 61.3-69.9 51.7 30.8-32.8 16.7
13 130-134 37.5 72.2-89.7 58.6 33.8-63.4 33.3
0-22.1 74.3 10 90.6-128.4 62 13
23-27.9 77.1 131.9-135 25 128.4-137.5 55.2 0-113.8 33.3
27.9-113.9 74.3 13 138.9-145,7 62
20 0-113.9 end 25 13
0-8.2 54.3 16 0-113.8 65.5
8.2-14.6 57.1 85.6-89.7 25 20
14.6-15.5 60 17 0-11.9 58.6
16.6-23.5 65.7 26-81.2 end 25 12.5-20.2 62.1
25-26.1 68.6 20 21.5-26.1 65.5
26.1 71.4 0-63.4 end 25 29.4 68.9
29.4-48.7 74.28 21 30.8-34.2 75.9
49.3-63.4 74.4 0-46.9 25 34.9-63.4 79.3
2 6
19.5-34.4 20 0-40.8 31
34.4-74.5 22.8 42-62.5 27.6
74.5-88.3(end) 20 63.7 31
5p 65-69.9 24.1
0-43 22.8 71-143.4 20.7
43-45.6 20 144.4-149.5 17.2
6 149.5-156.9 20.7
0-29.3 25.7 158.2-170.5 17.2
29.3-58.6 28.6 9
58.6-71 25.7 0-29.2 20.7
71-170.5 22.85 29.6-129 17.2
9 130-134.2 20.7
0-29.17 20 10
10 0-37.2 37.9
0-38.8 20 37.8-132.6 31
38.8-87.4 22.85 132.6-135.2 20.7
88.28-104.9 20 11
106.1-135(end) 22.85 0-42 20.7
11 43-57.4 24.1
0-50.5 22.85 59.5-60 20.7
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65.1-97.7 20 61.4-73 24.1
97.7-112.4 22.85 74.3-74.39 20.7
112.4-134.6 25.7 75.7-134.6 17.2
16p 17
0-31.1 25.7 45.2-66.7 20.7
31.1-56.6 20 69.2-81.2 20.7
17 19
51.5-66.7 20 0-51.7 34.5
19 52.1-63.7 31
0-63.7end 22.85 21
21 0-46.9 end 31
0-41.6 25.7
41.6-46.9 22.85
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7. Losses at specific BAC clone sites
>5yrMSI- % >5yrMSI- % <5yrMSI- % <5yrMSI+ %
1 20 1 1
0-7.4 74.3 0-63.4 50 0-23.6 70 0-45 83.3
8.9-24.2 77.1 1 23.8-32 66.7 45.2-45.9 66.6
26.6-32.9 74.3 0-245 end 25 32.6-34.6 63.3 46.2-118.9 50
33.8-43.6 71.4 13 36.3-40 60 140.9-245 33
44.1-45.9 62.8 0-53.8 25 40.5-50.3 56.7 8
46.6 57.1 17 51.3-97.4 53.3 0-34.1 50
46.6-52.7 60 0-20.1 37.5 98.2-110.2 50 34.3-37 33.3
53.2-53.4 54.3 21 111.6-113.7 46.7 38-40.1 16.7
54.5-69.5 51.4 0-46.8 25 113.7-118.9 43.3 9
70.1-81.4 48.6 22 140.9-161.9 33.3 0-29.5 33.3
82 45.7 0-49.3 37.5 162.2-196.8 30 64.7-119.9 50
83.1-84.5 40 198.7-245 33.3 119.9-134.2 66.6
85.4-118.9 42.8 8p 17
141-142.7 31.4 0-30.7 50 0-20.2 50
143.2-145.2 28.6 31.7-34.3 46.6 25.2-26.7 16.7
145.2-175.3 25.7 35-38 43.3 19
176.3-180.2 28.6 39.5 40 0-63.6 50
180.2-192.8 31.4 40.1 33.3 16
193.9-200.9 34.3 40.1 30 65.2-89.7 33.3
200.9-218.3 31.4 40.9 26.7 18
218.3-220.4 34.3 41-41.8 23.3 18.8-77.6 33.3
220.4-224 31.4 42.2-42.9 13.3 20
224-245 28.6 14 0-20.1 33.3
8p 0-105.1 40 22
0-31.7 48.6 17 21.4-49.2 66.7
31.7-32.7 45.7 0-20.1 70
34.1-34.3 42.8 25.2-28.4 33.3
34.3-36.2 40 29.2-34.9 30
36.2 37.1 35.8-40.8 26.7
37 28 40.9-41.8 23.2
38 25.7 42.1-43.3 20
39.5-41.9 22.8 18
17 0-18.9 63.3
0-20.1 68.6 19.7-24.4 60
25.2 40 25.7-42.9 63.3
25.2-26 31.4 43.5-77.6 end 66.7
26.7-44.1 28.6 22
45.2-48.5 25.7 0-49.2 end 66.7
48.9-50.9 28.6
51.5-66.7 25.7 4
67.3-81.2 28.6 0-8.3 33.3
18 10.3-55 30
0-14.9 60 56-191.3 26.7
18.8-48.1 62.8 5
48.4-65.9 65.7 49.9-53.3 20
66.5-77.6 62.8 55.4-71.7 23.3
22 72.8-89.6 20
0-36.8 62.8 90.8-109.4 23.3
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37.6-49.3 65.7 110.1-118.3 20
4 9
179.7-191.3 22.8 0-25.7 26.7
9 26.5-29.1 30
0-29.6 28.6 29.5 26.7
64.8-117.4 25.7 64.7-134.2 23.3
10 10
69.7-77 20 85.7-101.1 20
88.2-104.9 20 15
14 0-47.5 30
0-25.6 34.3 48.8-62.2 26.7
26.5-60.9 31.4 62.9-99.7 23.3
62.3-105.1 34.3 19
15 0-51.7 30
0-53.2 40 51.7-63.3 33.3
54.8-99.7 37.1 20
19 0-11.8 23.3
0-49.1 25.7 12.5-20.1 20
20 21
0-14.6 25.7 0-46.8 23.3
15.5- 22.8
16.6-17.8 17.1
21
0-30.7 34.3
32.9-41.6 31.4
42.6-46.9 end 34.3
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8. Small areas of gain (<10Mb)
5 yr +/MSI- 5 yr +/MSI+ 5yr-/MSI- 5yr-/MSI+
Chr1 82-86 80-86
0-7.4 183.8-192.8
81.4-84.5 113.9-118
Chr2 31.5-34.4
189-209
Chr 3 66.7-74
Chr5 40.1-49.9
Chr6 149.5-156.9
Chr7 98.5-101 0-2.4
20-23.5
67.4-end
Chr8 142.3-145.7
Chr9 129-134 130-134.2
Chr10 41-48 130.9-135.2 75-83
132.6-135.2
Chr12 0-4.1 0-4.1
66-74.7
Chr13 19.1-27.9 19.1-27.9
22-27.9
Chr15 25-34
Chr16 0-7
84.6-89.7
Chr17 44.1-48.5 80-83
Chr18 77-80
Chr20 15.5-17.8 0-9.3
206
16.1-22.5
9. Small areas of loss (<10Mb)
5yr+/MSI- 5yr+/MSI+ 5yr-/MSI- 5yr-/MSI+
Chr2 129.9-136
236.4-242
Chr4 0-8.3
Chr7 62-67
Chr9 25.7-29.1
Chr10 68-77
Chr11 73-81
104.4-107.9
Chr12 74.7-82.3
Chr17 48.5-50.9
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10. Areas of greater than single copy number change
5yr+/MSI- 5yr+/MSI+ 5yr-/MSI- 5yr-/MSI+
Chr1 140-152.8 161-209
113.9-118
Chr2 34.4-74.5 31.5-34.4
187-225 129.9-136
Chr3 66.7-74.5 90-94
Chr4 0-37
Chr5 126.1-135.8
Chr6 2x p arm
Chr7 p arm 0-14.7 31-40
98.5-101
Chr8 3x q arm 143-146 q arm 80-145
102-146
Chr10 41-48 130.9-135 73-83
52-70
Chr11 5-20
43-48
77-81
Chr12 1x p arm 0-38
Chr13 19.1-27.9 6x whole chr 2x whole
chr
Chr 18 77-80 18.9-42.9
Chr 20 3x whole chr 60-66 6x whole chr 16.6- 22.5
5 x q arm 2x q arm 29.4-47
42-46 30-65
33-50 50-65
208
29.4-63.4
11. Summary of adenoma aCGH changes.
Adenoma Regions of change in Mb
1 1, 0-54,del; 6,33-47,del; 8,all,gain; 9,122-ter,del; 13,all,gain; 16,0-
31,del; 16,67-ter,del; 17,0-50,del; 19,all,del; 20,all,gain; 21,all,gain;
22, all,del
2 1,0-51,del; 2,123-152,del; 17,all,del; 19,all,del
3 1, 0-57, del; 9,104-111, del ; 17,0-50,del
4 1, 0-47, del; 17, 0-50, del; 22,all,del
5
6 1, 0-46, del; 17, 44-50,del
7 1, 0-46,del; 10,91-103,del; 18,51-64,del; 19,all,del
8 1,0-46,del; 7,62-74,del; 9,123-ter,del; 12,111-ter,del; 13,53-96,gain;
16,0-31,del; 16,66-ter,del; 17,0-50,del; 17,72-ter,del; 19,0-18,del;
19,38-ter,del; 20,31-36,del; 22,all, del
9
10 1, 0-51, del
11 13, all, gain
12
13 17, 0-14, del
14
209
